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ABSTRACT 
Brain derived neurotrophic factor (BDNF) is widely studied for its role in 
plasticity that underlies learning and memory, and the maladaptive plasticity that gives 
rise to chronic pain. BDNF acts through its receptor, tropomyosin kinase B (TrkB), to 
initiate signaling cascades that result in time-, sex-, region-specific changes in 
nociceptive circuitry due to nerve injury. Despite great interest in the role of BDNF in 
neuroplasticity responsible for producing chronic pain states, including neuropathic pain, 
very few studies include more than one timepoint, region, sex, and methods to evaluate 
the presence and activity of BDNF. These gaps in the literature are especially problematic 
when considering reported sex-dependent or contradictory effects of BDNF on pain 
behaviors. Understanding the scope and exact mechanism of BDNF-TrkB signaling in 
neuropathic pain is crucial for the development of novel pain therapies that are safe, 
effective, and unbiased.  
 My thesis work focuses on providing a comprehensive assessment of BDNF and 
TrkB expression and function which includes both sexes, multiple regions of the 
nociceptive pathway, cell types, and timepoints after nerve injury. Using a highly 
sensitive in situ hybridization method, I show that changes in BDNF and TrkB mRNA in 
DRG and spinal cord are time- and sex-dependent. Although males had higher amounts 
of TrkB protein in dorsal horn (DH) of the spinal cord, the degree of TrkB activation due 
to injury was comparable between the sexes. A novel TrkB specific inhibitor, ANA-12, 
modestly but significantly reduced hypersensitivity in males in a time-dependent manner 
but not in females. Further investigation into this revealed that ANA-12, instead of 
inhibiting TrkB activity, increased DH TrkB phosphorylation in both sexes. Finally, the 
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role of microglia in BDNF-TrkB signaling was investigated and although BDNF mRNA 
was not detected in any microglial profiles in DH, TrkB mRNA was reliably identified in 
DH microglia after nerve injury. The microglial TrkB phosphorylation was elevated in 
DH of injured animals pointing to a functional role. To test that hypothesis, I generated a 
tamoxifen inducible microglia specific TrkB knockout line and conducted behavioral 
experiments to evaluate the effect of microglial TrkB on pain behaviors. No behavioral 
differences were detected at any timepoint in either sex. Surprisingly, tissue analysis 
revealed an elevation in BDNF and TrkB along with the surface area of microglia in DH 
indicating increased microglial activation in response to microglial TrkB deletion. These 
data collectively suggest that BDNF-TrkB activity is region, sex, and time-dependent and 
highlights the importance of validating not just the tools used, but also the effect of the 
manipulations on the underlying process that is being studied.
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Chronic pain affects about 20% of the population, costs upwards of $200 billion 
in lost productivity and health care costs, and makes up for about 10-15% of doctor’s 
visits (Stemkowski et al., 2013; CDC, 2018; CE et al., 2020). Chronic pain is defined as 
pain that persists or recurs for 3 to 6 months (CDC, 2018). The common treatments of 
pain are insufficiently efficacious and have significant long-term side-effects as well as 
unintended consequences such as opioid dependence and addiction. Neuropathic pain 
specifically is especially difficult to treat because opioid analgesics, which are currently 
the most prominent and commonly prescribed analgesics are not as effective in treating 
pain of neuropathic type (Abdulrahman and Alsafi, 2020). Newer classes of drugs 
including, GABA agonists, Selective serotonin reuptake inhibitors (SSRIs), and 
norepinephrine modulators have been found to be more effective in managing pain of 
neuropathic origin (Inoue, 2009). These clinical and pharmacological results suggest 
distinct pathology and neuroplasticity in the context of neuropathic pain as compared to 
other types of pain disorders.  
Neuropathic pain and nociceptive pathway 
Neuropathic pain is defined as pain originating because of injury or disease 
affecting somatosensory and nociceptive pathways. Somatosensory pathways convey 
information about touch, pressure, vibration, pain, and temperature from the end organs 
to the brain. Innocuous sensory stimuli are conveyed to the primary somatosensory cortex 
via the posterior-column medial lemniscus pathway. The nociceptive pathway, 
commonly referred to as the lateral spinothalamic tract (LST) or spinothalamic tract 
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(STT), carries information about painful stimuli. This pathway begins with primary 
sensory neurons of the pseudo-unipolar type which have two sets of processes or fibers, 
namely, peripherally projecting or centrally directed. The collection of cell bodies of 
these neurons is referred to as the dorsal root ganglia (DRG) which are nestled between 
spinal vertebrae. The peripherally projecting ends of the DRG neurons innervate 
epidermal layer of skin and can be activated by noxious stimuli presented to the skin. The 
centrally projecting fibers carry information from the peripheral organ to the dorsal horn 
of the spinal cord (superficial laminae). A dense network of excitatory and inhibitory 
neurons of the dorsal horn integrates the incoming innocuous and noxious stimuli and 
only about 1% of neurons in the DH are projection neurons that carry the integrated 
information to the thalamus. Axons of the projection neurons decussate at the spinal level 
and ascend to the contralateral ventral posterior lateral (VPL) and central nucleus of 
thalamus. A third order neuron from the VPL then sends information to the primary 
somatosensory cortex which gives rise to the conscious perception of the painful 
sensation. In addition, information from the central nucleus of thalamus is sent to many 
other brain regions including, amygdala, hippocampus, ventral striatum, anterior 
cingulate cortex which are responsible for the affective component of pain. Normally, the 
innocuous tactile sensory information is segregated from the pathways carrying noxious 
information. However, following nerve injury, the gating mechanisms and spinal 
circuitry that function to keep the two sensory pathways segregated breakdown and the 
innocuous information can be conveyed to the brain by the nociceptive pathway thus 
resulting in the sensation of pain generated by an innocuous stimulus (allodynia) 
(Bardoni and Merighi, 2009; Stemkowski et al., 2013). In addition to allodynia, the 
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existing nociceptive circuitry is sensitized such that noxious information is amplified to 
generate a greater sense of pain (hyperalgesia) (Bardoni and Merighi, 2009; Stemkowski 
et al., 2013). There are many changes throughout the ascending nociceptive pathway as 
well as the descending modulatory pathway that contribute to allodynia, hyperalgesia, 
and all the neuropathic pain components. However, the most well studied and understood 
mechanisms include changes that occur at the dorsal root ganglia (primary sensory 
neurons) and spinal cord (first site of signal convergence). Convergence and complexity 
of signal interpretation is greater at each higher level in the pathway. Therefore, most pre-
clinical research focuses on mechanistic changes at the lower levels in the nociceptive 
pathways because it is relatively simpler in terms of number of converging signals. 
Additionally, therapeutics targeting these sites are likely to have fewer disruptive effects 
on the central nervous system (CNS).  
Mechanisms of central sensitization 
Central sensitization is a term used to refer to the changes that occur at the spinal 
level which are thought to be primarily responsible for producing allodynia and 
hyperalgesia. Various mechanisms contribute to the neuronal sensitization. Some of these 
include signaling factors, growth factors, neurotransmitters, and peptides released into the 
dorsal horn by central processes of peripheral sensory neurons following injury (Bardoni 
and Merighi, 2009; Stemkowski et al., 2013; Khan and Smith, 2015; Garraway and Huie, 
2016; Richner et al., 2017). Several neuroimmune changes result in increased reactivity 
of local microglia and astrocytes that then release cytokines, chemokines, and signaling 
factors of their own that can directly or indirectly activate spinal neural circuits. 
Additionally, the expression of receptors for excitatory neurotransmitters and their open 
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probabilities are increased contributing to the increased sensitivity and response of spinal 
neurons. These mechanisms are thought to be responsible for hyperalgesia. Allodynia, on 
the other hand, is considered to arise due to spinal disinhibition that is triggered by 
microglial activity. Under normal conditions, the innocuous tactile information is gated 
by GABAergic inhibitory neurons that are part of the dorsal horn spinal circuits. 
Following nerve injury, these inhibitory gates are removed, and tactile information 
activates the nociceptive projection neurons and normally non-painful stimuli can 
produce a pain response (Chen et al., 2014a; Hildebrand et al., 2016). Microglia are 
thought to contribute to the disinhibition at the spinal level by releasing BDNF.  
Role of BDNF in the central nervous system  
Brain derived neurotrophic factor (BDNF) is a ubiquitous growth factor that plays 
a crucial role in neuronal survival, differentiation, and polarization during development. 
In the adult mammalian systems, it is thought to mediate long-term plasticity under 
various conditions (Borodinova and Salozhin, 2017). BDNF is produced in the neuronal 
endoplasmic reticulum and stored in large dense core vesicles at the axon terminals along 
with other neuropeptides. The mature form of BDNF (which is the form that will be 
referred to as BDNF in this thesis) is cleaved from its precursor, proBDNF, by proteases 
and convertases and thus are co-localized in large dense core vesicles. ProBDNF and 
mature BDNF are released from neurons in an activity dependent manner and broadly 
have opposing effects and different affinities for receptors(Borodinova and Salozhin, 
2017). proBDNF is thought to bind with p75NTR, a member of the tumor necrosis factor 
family, and results in long-term depression and cell death. In contrast, the mature BDNF 
has a higher affinity for its cognate receptor Tropomyosin kinase B (TrkB) which auto-
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phosphorylates upon BDNF binding and engages downstream substrates such as 
MAPK/ERK, PI3K and PLC. These pathways generally lead to activation of CREB thus 
bringing about long-term changes via gene-modification(Chen et al., 2014b; Borodinova 
and Salozhin, 2017).  
BDNF activity following injury 
BDNF is expressed in sensory neurons in DRG in baseline conditions and this 
expression increases following injuries(Obata and Noguchi, 2006; Marcol et al., 2007). 
Neurons of the spinal cord also express BDNF, and despite a lack of clear direct 
evidence, spinal microglia are thought to produce and release BDNF. Regardless of the 
source, the activity of BDNF at the spinal level has been shown to be necessary and 
sufficient for producing behavioral tactile hypersensitivity(Inoue, 2009; Stemkowski et 
al., 2013; Garraway and Huie, 2016). Intrathecal injections of BDNF have been shown to 
produce writhing, scratching behaviors which are suggestive of increased 
nociception(Marcol et al., 2007; Dhandapani et al., 2018). BDNF brings about these 
behavioral changes by sensitizing the nociceptive signaling pathways and causes long-
term changes that produces maladaptive neuroplasticity which maintains the neuropathic 
pain state. BDNF induced activation of intracellular proteins and kinases is linked with a 
wide range of outcomes. These include phosphorylation and modification of endogenous 
receptors such that their open probability and duration increases and results in rapid and 
long-lasting neuronal activity(Obata and Noguchi, 2006; Marcol et al., 2007; Ding et al., 
2015; Shaw et al., 2020). Additionally, activation of intracellular pathways can 
transiently or permanently increase or decrease receptor placement in the cell membrane. 
Furthermore, the long-term genetic changes can result in increased expression and 
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transcription of more receptors, kinases, and cellular material that can generate 
morphological changes.  
TRKB receptor types 
Tropomyosin receptor kinase B (TrkB) is a member of the receptor kinase family 
that functions as a cognate receptor for BDNF. All neurotrophins have an affinity for all 
neurotropin receptors, they have particularly high affinity for their cognate receptors (Lu 
et al., 2005; Ohira and Hayashi, 2009). TrkB has high affinity for BDNF and 
neurotrophin 3/4 (NT-3/4). The NTRK2 gene encodes for two main types of receptors, 
the full-length TrkB receptor (GP145) that contains intracellular kinase domains, and two 
forms of truncated TrkB (GP95) that lack intracellular kinase domains (Minichiello, 
2009). The T1 and T2 truncated TrkB receptor forms have 11 and 9 unique intracellular 
domains, the function of which is unclear. The full-length TrkB (fl-TrkB) was thought to 
be the active form which allowed for intracellular signaling due to the kinase domains at 
the C-terminus, whereas the truncated forms are assumed to play an opposing role by 
scavenging BDNF thus preventing binding and activation via fl-TrkB (Klein et al., 1991; 
Middlemas et al., 1991; Squinto et al., 1991; Barbacid, 1994). However, more recent 
evidence suggests that the truncated form, T1, can produce intracellular calcium signaling 
(Cao et al., 2020). The precise mechanisms by which the intracellular signaling is carried 
out in the absence of an internal kinase domain is not known.  
TRKB receptor expression and function 
Like BDNF, TrkB is expressed widely and ubiquitously throughout the CNS (Yan 
et al., 1997; Mannion et al., 1999). Although TrkB expression in non-neuronal cells has 
not extensively been characterized, ultra-structural images show TrkB receptors localized 
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to axons, dendrites, and cell bodies of neurons in the brain and spinal cord (Yan et al., 
1997). In sensory neurons, fl-TrkB receptor is expressed in cell bodies located in the 
DRG and the central axonal terminals that project to superficial laminae of the dorsal 
horn of spinal cord (Minichiello, 2009; Vaegter et al., 2011; Richner et al., 2017, 2019; 
Dhandapani et al., 2018). The truncated T1 form is expressed in astrocytes in the spinal 
cord and brain (Cao et al., 2020) . TrkB normally exists as a monomer, and it dimerizes 
upon BDNF binding (Minichiello, 2009). The downstream signaling which includes 
activation of PLC, MAPK/ERK, and PI3K are responsible for BDNF induced neural 
plasticity (Klein et al., 1991; Middlemas et al., 1991; Barbacid, 1994; Merighi et al., 
2008; Minichiello, 2009; Ohira and Hayashi, 2009). BDNF-TrkB signaling plays a 
crucial role in LTP mechanisms in the CNS (Ohira and Hayashi, 2009; Khan and Smith, 
2015). Similar LTP mechanisms contribute to maladaptive plasticity underlying many 
pathophysiological conditions, including neuropathic pain (Pezet et al., 2002; Merighi et 
al., 2008; Ohira and Hayashi, 2009; Cao et al., 2020). The exact localization of TrkB in 
different cell types has not been studied largely due to the absence of validated antibodies 
for the detection of fl-TrkB-immunoreactivity (-ir) as well as the truncated TrkB-ir. 
Majority of the data regarding expression of TrkB in various neuropathic pain states is 
measured via Western blot assay which does not provide information about the 
anatomical localization of the receptors. Furthermore, the activity of the TrkB receptors is 
often measured indirectly by quantifying the presence or activation of downstream 
markers that are thought to be activated by TrkB. Therefore, it is difficult to assess the 
presence of TrkB in various cell types and to quantify the expression of TrkB specifically 
in areas of CNS that process nociception.  
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Glial cell function in CNS 
 When glial cells were first discovered, they were believed to serve as the glue or 
binding agent in the CNS, however, it is clear from the mounting data that glial cells are 
crucial for neuronal signaling. There are five main classes of glial cells- satellite cells, 
Schwann cells, oligodendrocytes, astrocytes, and microglia. Schwann cells are glial cells 
expressed in the PNS. These cells envelop fiber tracts of primary sensory neurons and are 
responsible for nerve fiber myelination. Oligodendrocytes are found in the CNS and play 
a similar role to Schwann cells. Oligodendrocytes engage in signaling with cells and 
neurons to prevent neuronal regeneration in the CNS (Ji et al., 2013). Satellite cells are 
found surrounding DRG neurons. These cells can produce signaling factors and express 
receptors for various factors released by DRG neurons and peripheral immune cells. 
Satellite cells in turn can participate in DRG neuronal modulation by altering their 
excitability. Astrocytes are by far the most abundant glial cells in the CNS and are closely 
associated with neurons. Astrocytes not only provide neurons with essential factors 
required for their proper function, but also maintain proper extracellular environment. 
Astrocytes form dense non-overlapping networks with each other via gap junctions and 
are thought to control large and small blood vessels to increase blood flow to most active 
brain regions. Astrocytes even form tripartite synapses with axon terminals thus 
participating, modulating, and influencing neuronal signaling (Vallejo et al., 2010). 
Microglia are derived from the peripheral monocyte lineage and are the native immune 
cells of the CNS. These cells serve as sentinels and scan their environment for signs of 
damage (Ji et al., 2013).   
Microglial activity following injury 
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Microglia function as the primary immune cells in the CNS. Under normal 
conditions, microglia exist in their quiescent state and are relatively stable as they 
monitor microenvironments for disruptions, injuries, or damage. When they detect 
presence of foreign objects or increased signals indicating damage, they become activated 
and upregulate expression of various proteins, including Iba1, a marker used to label 
microglia. Iba1 stands for ionized calcium binding adaptor molecule 1 (Ito et al., 1998), 
and is an actin-binding protein found in microglia and macrophages. It is responsible for 
membrane ruffling and via rac signaling it engages an intracellular signaling cascade that 
results in phagocytosis, microglial and macrophage proliferation, and infiltration of 
peripheral lymphocytes, monocytes, macrophages to the CNS (Ohsawa et al., 2000; Imai 
and Kohsaka, 2002; Kanazawa et al., 2002; Ramesh et al., 2013; Guan et al., 2015).  
These cells are phagocytotic and along with other immune cells recruited to the site of 
injury are responsible for cleaning up byproducts and damaged components resulting 
from the injury. 
Contribution of microglia to nerve injury induced neuroplasticity 
The contribution of microglia to nerve injury related spinal neuroplasticity has 
received a lot of attention and interest in recent years (Moalem and Tracey, 2006; Ji et al., 
2013; Ramesh et al., 2013). Following peripheral nerve injury, the primary sensory 
neurons release Colony stimulating factor 1 (CSF1), along with many other signaling 
factors such as BDNF, in the spinal dorsal horn. CSF1 binds to its receptor, CSF1R, 
located on spinal microglia which causes their activation. Several downstream 
mechanisms including phosphorylation of p38 MAPK leads to changes that produce 
behavioral hypersensitivity (Jin et al., 2003; Tsuda et al., 2004; Ji and Suter, 2007). 
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Blocking microglial activation by non-specific microglial inhibitors, toxins or specific 
receptor blockers designed to inhibit certain microglial functions can reduce behavioral 
hypersensitivity (Jin et al., 2003; Raghavendra et al., 2003; Tsuda et al., 2004; Verge et 
al., 2004; Ledeboer et al., 2005; Clark et al., 2007; Guan et al., 2015). Microglia are 
assumed to contribute to spinal neuroplasticity by releasing BDNF thus contributing to 
the BDNF-TrkB signaling which sensitizes nociceptive circuitry (Coull et al., 2005; Chen 
et al., 2014b). However, these reports provide indirect evidence for the presence and 
release of BDNF from spinal microglia following nerve injury. The studies indicating 
microglial release of BDNF are conducted in vitro using microglial cell-cultures or in 
vivo using antibodies whose specificity for BDNF was not evaluated (Coull et al., 2005; 
Ulmann et al., 2008). Therefore, there is no evidence that microglia express BDNF and 
the contribution of this microglial BDNF to nerve injury induced hypersensitivity.  
Sex differences in spinal mechanisms of neuroplasticity 
There is compelling evidence for sex differences in various physiological 
processes involved in neuroplasticity (Berkley, 1997; Greenspan et al., 2007; Fillingim et 
al., 2009; Manson, 2010; Mogil, 2012, 2020; Sorge and Totsch, 2016; Doyle et al., 2017; 
Mapplebeck et al., 2018, 2019). For instance, many chronic pain conditions are more 
prevalent in women than in men, the intensity and duration of the pain conditions is 
higher in women (Greenspan et al., 2007; Fillingim et al., 2009; Manson, 2010; Mogil, 
2012). In preclinical studies, many biological pathways involved in immune function 
after injury are different between male and female animals (Berkley, 1997; Greenspan et 
al., 2007; Fillingim et al., 2009; Manson, 2010; Mogil, 2020; Sorge and Totsch, 2016; 
Doyle et al., 2017; Mapplebeck et al., 2018, 2019). In the neuropathic pain literature, a 
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few reports gained attention due to their surprising conclusions that BDNF, microglia, or 
some aspect of BDNF-TrkB signaling or immune function do not contribute to 
nociceptive plasticity in females as it does in males (Greenspan et al., 2007; Manson, 
2010; Mapplebeck et al., 2017, 2018; Mogil, 2020). However, these studies do not point 
to any mechanistic rationale for the observed sex-differences because basic functional 
information in females is largely absent. Almost all the current data available for the 
mechanisms underlying pain related neuroplasticity is collected from male subjects 
(Mogil, 2020). Therefore, the mechanistic explanations and points of divergence for 
observed behavioral sex differences remain elusive. The most influential report in the 
spinal neuroplasticity literature announced that microglia are dispensable in spinal 
neuroplasticity following nerve injury in females and instead peripheral T-cells infiltrate 
the CNS (Sorge et al., 2015; Sorge and Totsch, 2016). These results generated great 
interest, however, follow up studies that measured, and evaluated the signaling 
downstream of the supposed microglial functions did not show sex-differences, 
indicating that many signaling cascades converge and therefore would be promising 
targets in novel pain therapies (Mapplebeck et al., 2019). New mandates to include 
female subjects in all experimental protocols, with few exceptions, will provide a good 
base of knowledge regarding previously ignored factors that contribute to inadequate 
research regarding pain treatment in women. All experiments conducted here included 
female subjects not solely to demonstrate sex-differences, but to provide a broad 
framework for understanding BDNF-TrkB signaling in both sexes.  
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DISSERTATION OBJECTIVES 
Information presented so far provides rationale for targeting components of the BDNF-
TrkB signaling pathway for development of novel analgesic therapies. However, the 
ubiquity of BDNF-TrkB signaling in the central nervous system (CNS) poses a major 
problem for BDNF-TrkB inhibition as a target for pain therapies. Furthermore, the 
literature on region, sex, and time-specific expression and function of BDNF via its 
receptor in the context of nociceptive plasticity is greatly lacking. Prior studies have 
shown increased expression or function of BDNF, typically by proxy due to a lack of 
tools to directly visualization or quantification of BDNF or its receptor TrkB, at single 
timepoint, sex, or region of the CNS. Thus, the interpretation of data showing analgesic 
effects of BDNF or sex-differences in BDNF-TrkB signaling in neuropathic pain is 
challenging due to the absence of a comprehensive characterization of time, region and 
sex-specific changes following nerve injury. Understanding the region, sex, time, and 
injury specific changes, as well as evaluating the efficacy or action of tools used to study 
those changes that underlie maladaptive neuroplasticity is crucial for the development of 
effective pain strategies. 
Towards this goal, my thesis research had three main objectives: 
Chapter 1: Comprehensive characterization of BDNF and TrkB expression in regions of 
nociceptive pathway initially affected by peripheral nerve injury at several time-points 
after injury in animals of both sexes. 
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 Chapter 2: Determine the degree of sex- and time-dependent TrkB activation after injury 
and evaluate whether TrkB activity is required for the establishment and maintenance of 
chronic hypersensitivity.  
Chapter 3: Understand the role of spinal microglia in the BDNF-TrkB signaling and 





CHAPTER 1: BDNF AND TRKB EXPRESSION IN DRG AND SPINAL CORD 
FOLLOWING NERVE INJURY  
INTRODUCTION 
Brain derived neurotrophic factor has a crucial role in neuronal development and 
is known to contribute to neuronal survival, neuronal proliferation, axonal growth, and 
neuronal migration (Lu et al., 2005). In the adult CNS, BDNF participates in mechanisms 
underlying neuroplasticity (Bramham and Messaoudi, 2005). Since chronic pain is a 
result of maladaptive plasticity in nociceptive pathways, BDNF is widely studied to 
understand mechanisms by which it causes long-term changes that result in chronic pain 
(Pezet et al., 2002). Although BDNF is greatly increased following inflammatory insults, 
modest increases in BDNF at specific timepoints after nerve injury have been reported 
(Pezet et al., 2002; Bramham and Messaoudi, 2005; Marcol et al., 2007; Merighi et al., 
2008; Smith, 2014). BDNF is produced in DRG neurons and released into the spinal cord 
following nerve injury leading to an increase of BDNF in spinal dorsal horn (Pezet et al., 
2002; Bramham and Messaoudi, 2005; Obata and Noguchi, 2006; Merighi et al., 2008; 
Chen et al., 2014b; Smith, 2014). In addition to the sensory neuron derived BDNF, it is 
also released by neurons in the superficial laminae of spinal cord (Pezet et al., 2002; 
Bramham and Messaoudi, 2005; Obata and Noguchi, 2006; Merighi et al., 2008; Chen et 
al., 2014b; Smith, 2014). Microglia are considered to play a critical role in spinal 
neuroplasticity by releasing BDNF into the surrounding areas of spinal cord (Coull et al., 
2005; Inoue, 2009; Biggs et al., 2010). Regardless of the source, BDNF induces short- 
and long-term changes in the spinal cord that together increase activation of projection 
neuron that carry nociceptive information from spinal cord to higher brain regions 
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(Marcol et al., 2007; Merighi et al., 2008; Smith, 2014). The short-term changes include 
phosphorylation of presynaptic NMDA receptors, which increases release of glutamate 
and other factors into the spinal cord, phosphorylation of pre- and post-synaptic NMDA 
and AMPA receptors to increase their open channel probability and duration leading to 
increased excitability of spinal neurons, and increased trafficking of glutamate receptors 
in neuronal membranes (Marcol et al., 2007; Merighi et al., 2008; Chen et al., 2014b; 
Sikandar et al., 2018). BDNF-induced long-term changes alter the nociceptive circuitry 
such that innocuous stimuli can activate the nociceptive projection neurons (Bramham 
and Messaoudi, 2005; Coull et al., 2005; Obata and Noguchi, 2006; Obata et al., 2011; 
Zhou et al., 2011; Li et al., 2017; Sikandar et al., 2018). These short-and long-term 
changes results in long-term plasticity (LTP) in spinal nociceptive circuits. All these 
effects of BDNF are carried out by signaling through fl-TrkB, and methods that inhibit 
TrkB (such as TrkB antagonists, blockers, anti-TrkB antibodies, and genetic mutations to 
block TrkB function) reduce nerve injury induced hypersensitivity (Groth and Aanonsen, 
2002; Yajima et al., 2002; Reichardt, 2006; Merighi et al., 2008; Ohira and Hayashi, 
2009; Wang et al., 2009; Sorge et al., 2015; Hildebrand et al., 2016; Li et al., 2017; 
Dhandapani et al., 2018; Cao et al., 2020; Ikeda et al., 2020). Taken together, BDNF and 
TrkB have been independently shown to contribute to nerve injury induced behavioral 
hypersensitivity and increase excitability in spinal cord.  
 Most studies do not directly measure BDNF or TrkB expression levels in spinal 
cord or DRG because of the lack of validated, reliable, and sensitive antibodies and in 
situ techniques. The few reports of BDNF increase following injury includes in situ and 
IHC experiments that showed elevated BDNF mRNA and protein levels at multiple 
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timepoints after injury but only included male animals (Michael et al., 1999; Obata et al., 
2003; Geng et al., 2010). Transgenic mouse lines are often used to visualize BDNF 
and/or TrkB in different CNS regions, however, the reports from these studies contradict 
data collected from wildtype (WT) animals and thus raise the possibility of altered 
protein regulation in transgenic mice. Again, in all these examples only male subjects are 
included, therefore no information about BDNF and TrkB expression or function is 
available in females. Many potential explanations exist for the observed behavioral or 
pharmacological sex-differences (Manson, 2010; Mogil, 2012; Sorge and Totsch, 2016; 
Mapplebeck et al., 2017, 2019), however, without any information regarding the 
expression and localization of BDNF and TrkB in females, it is difficult to study the point 
of divergence in these nociceptive signaling pathways. This study aims to fill that gap in 
the literature by quantifying the BDNF and mRNA expression in DRG neurons, satellite 
cells, as well as superficial laminae of dorsal horn of the spinal cord at multiple 
timepoints following peripheral nerve injury in male and female mice. The results 
presented in this thesis will provide comprehensive data on BDNF and TrkB expression 
in sex-, time-, and region-specific manner and serve as a necessary reference point for 
future studies aimed at understanding the root cause of observed sex-differences. 
 17 
 
MATERIALS AND METHODS 
Animals 
All experiments were conducted in compliance with National Institutes of Health 
Guide for Care and Use of Laboratory Animals and approved by the University of 
Minnesota Institutional Animal Care and Use Committee. Adult male and female ICR-
CD1 mice were bred in-house at University of Minnesota vivarium where male mice 
were housed 4 to a cage, and 5 female mice to a cage. They were kept at uniform 
temperature, humidity, 12-hour light/dark cycle with ad libitum access to food and water 
in a specific pathogen free environment. All animals were group housed for the entirety 
of all experiments, unless specific unrelated health issue required individual housing.  
Spared Nerve Injury (SNI) 
Tactile hypersensitivity was induced using the spared nerve injury (SNI) model as 
described by Decosterd and Woolf(Decosterd and Woolf, 2000). Mice were placed under 
isoflurane anesthesia in a recumbent position and the three terminal branches of the left 
sciatic nerve were exposed by bluntly dissecting the left thigh muscle. The common 
peroneal and tibial nerves were ligated using a 5.0 silk suture.  The peroneal and tibial 
nerves were cut 2 mm distal to the ligation site, leaving the sural nerve uninjured. Sham 
animals had the left sciatic nerve exposed without ligation or cutting of the nerves.  
Tactile Hypersensitivity 
Mice were acclimated to the testing room prior to each behavioral test session 
starting the day of baseline measurements. Mice were brought into a quiet testing room 
and allowed to acclimate for about an hour before placing them on a wire mesh grid 
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platform under a glass enclosure and allowed to acclimate for 30 mins prior to testing. 
Synthetic Von Frey filaments were used to apply force onto the lateral plantar surface of 
the left and right hind paw. Using the up-down method as described by Chaplan et al 
(1994) and statistical framework by Dixon (2012), the 50% withdrawal threshold was 
calculated wherein a positive withdrawal reflex was defined as a flinching, retracting, or 
withdrawing of the hind paw from the filament. Baseline tactile thresholds were 
measured for all animals in these experiments and measured again following nerve injury 
but prior to tissue collection.  
Spinal Cord and DRG tissue section preparation 
Mice were deeply anesthetized with isoflurane and perfused via the heart with 
calcium-free Tyrode’s solution (116mM NaCl, 5.4mM KCl, 1.6mM MgCl·26H2O, 
0.4mM MgSO·47H2O, 1.4mM NaH2PO4, 5.6mM glucose, and 26mM Na2HCO3) 
followed by fixative (4% paraformaldehyde). Tissues were dissected, post-fixed 
overnight in (4% paraformaldehyde), then incubated in 10% sucrose. Spinal cords and 
DRG were embedded in OCT compound (Tissue-Tek), flash frozen using liquid CO2 and 
stored at -80°C overnight. Sections were cut at 14 μm thickness using a cryostat 
microtome (OTF5000, Bright Instruments) and thaw mounted onto Superfrost Plus 
microscope slides (Fischer Scientific). Sliced spinal cord sections were anatomically 
mapped to determine slides within the L3 and L4 spinal levels. Spinal cord and DRG 
slides were stored at -20°C until further processing. Separate tissue blocks were made for 
tissues collected from each timepoint such that tissues from different timepoints were 
analyzed separately but comparisons were made between groups within the same 
experimental timepoint.  
RNAscope Processing and Probes 
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Slides were prepared for RNAscope® processing using the RNAscope® 
Fluorescent Multiplex v2 Kit (Cat. No.  323100). Briefly, slides were recovered from -
200 C, air-dried, and incubated in 4% paraformaldehyde for 5 mins. Tissue sections were 
dehydrated in ethanol solutions of increasing concentration (50%, 70%, 100% EtOH) for 
5 mins in each solution. Slides were washed with 1X PBS for 2 mins then tissue sections 
were covered with hydrogen peroxide (ACDBio) for 10 mins. Slides were washed 4 
times with distilled water, incubated in target retrieval reagent heated to ~960 C for 4 
mins, washed again 4 times in distilled water, then submerges in fresh 100% ethanol for 5 
mins. A hydrophobic barrier was drawn around the tissue and allowed to dry at room 
temperature for 30 mins. After drying, tissues were covered in RNAscope Protease III 
and placed in a warm 40°C humidified chamber for 15 mins. After removal from oven, 
slides were washed 4 times in distilled water.  
Following slide and tissue preparation, mRNA was tagged using highly specific 
probes and associated fluorophores for visualization. Briefly, excess water was removed 
from slides and BDNF (cat# 424821) or NTRK2 (cat#423611), positive- and negative-
control probes were added to separate slides and incubated for 2 hours at 40°C. 
Following incubation with probes, slides were washed 2 times in 1X wash buffer for 2 
mins. Probe signal was amplified by incubating tissue sections with Multiplex FLv2 
AMP1 and AMP2 for 30 mins, and in AMP3 for 15 mins at 40°C. Slides were washed 2 
times in 1X wash buffer for 2 mins in between each amplification incubation and 
following the last amplification step. Horseradish peroxidase channel 1 (HRP-C1) signal 
was developed by covering tissue in RNAscope multiplex FL v2 HRP-C1 and incubated 
for 15 mins at 40°C. Slides were washed for 2 mins with 1X wash buffer and Cyanine 3 
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(PerkinElmer) diluted in TSA buffer (1:1,500) was added to the slides. Slides were 
incubated with Cy3 for 30 mins at 40°C. Slides were washed twice with 1X wash buffer 
for 2 mins, RNAscope multiplex v2 HRP blocker was added to the slides, incubated for 
15 mins at 40°C, then washed 2 times in 1X wash buffer for 2 mins. DAPI was added to 
the slides for 30 seconds and cover-slipped using FluoroSave reagent (EMD Biosciences, 
Inc.). Slides were stored at room temperature. RNAscope® 20zz probes were ordered 
from ACDbio. The Ms-BDNF probe targeting 729-1974 mRNA region which recognize 
a common portion of the BDNF protein in all of the different translated proteins  
(NM_007540.4) and Ms-NTRK2 probe targeting 668-1582 mRNA regions encoding for 
FL-TrkB and truncated TrkB (NM_008745.3) 
Image Acquisition and Analysis 
Images were captured using a confocal Nikon A1R multiphoton confocal 
microscope or Olympus Fluoview upright confocal microscope at the University of 
Minnesota Imaging Center, with guidance from Dr. Guillermo Marquis. All images were 
collected on the same day or consecutive days with identical settings for all groups for 
direct comparison. A 25X objective was used when images were collected using the 
Nikon A1RMP, whereas a 20X objective was used to image tissues on the Olympus 
Fluoview Upright microscope. FIJI (FIJI is just ImageJ software from National Institutes 
of Health) was used for all image quantification. Macros were created to automate many 
of the repeated image processing steps. 
Quantification in DRG 
For quantification of the BDNF and TrkB mRNA L3 and L4 DRG ipsilateral to 
the injury were imaged. Three equally spaced sections were imaged for each DRG. For 
spinal sections, three equally spaced sections within the L3-L4 lumbar level were 
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selected and imaged. Images consisted of three channels for DRG images – namely, 
DAPI, an Alexa488 Dk anti-mouse secondary which provides background fluorescence 
to visualize tissue sections, and Cy3 tagged BDNF or TrkB mRNA. Gain, exposure, and 
offset settings were determined by using negative control probes and high mRNA signal 
containing tissues to determine optimal imaging parameters to avoid overexposure and 
underexposure. Satellite cells of the DRG were detected using the default auto threshold 
method and converting the image into a binary for a particle analyzer set to detect 
particles greater than 1micron. DRG neurons were manually circled by an observer 
blinded to the experimental details and groups using background observed in the 488-
fluorescence channel and using DAPI staining to restrict neuron outlines to those whose 
nuclei are visible to avoid potential double-counting. Surface area of neurons was 
measured in microns by calibrating the image size based on image acquisition 
parameters. Manually determined cell outlines were used as ROIs and default auto-
threshold was used to create an unbiased thresholding method. Signal above this 
threshold was considered positive signal. The area occupied by positive mRNA 
fluorescence was measured along with mRNA fluorescence as a function of area of the 
cells. Data from three sections were averaged to get single value for each L3 and L4 
DRG per animal, and values from L3 and L4 were added to get a single distribution of 
neurons by size and mRNA signal.  
Quantification in spinal cord sections 
For quantification in spinal cord sections, a similar approach was used to quantify 
BDNF and TrkB mRNA in DRG sections. Images of spinal dorsal horn consisted of 
DAPI channel and Cy3 tagged BDNF and TrkB mRNA.  Gain, exposure, and offset 
settings were determined by using negative control probes and high mRNA signal 
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containing tissues to determine optimal imaging parameters to avoid overexposure and 
underexposure. ROIs were manually drawn to outline dorsal horn of spinal cord using 
DAPI staining by observer blinded to experimental details or knowledge of animal 
groups. Spinal cord images were thresholded using the default auto-thresholding method 
and the area of mRNA signal and percent of mRNA area as a function of ROI size were 
measured. Data from three spinal sections were averaged to obtain a single value 
representing mRNA signal in spinal cord per animal. To quantify nuclear mRNA, auto-
thresholding methods and particle analyzers were used to automatically outline nuclei 
using DAPI staining, and the mRNA signal within these profiles were measured. The 
nuclear signal was subtracted from the total mRNA signal in the Dorsal horn to obtain the 
extra-nuclear signal in the spinal cord. 
Western blot assay 
Mouse spinal cords were harvested by hydraulic extrusion. The lumbar 
enlargement was isolated and divided into ipsi- and contralateral halves before being 
homogenized in RIPA solubilization buffer (Phosphate buffered Saline (PBS) with 0.1% 
IPEGAL (ICN Biomedicals), 12mM sodium deoxycholate, and 0.1%SDS) containing 
protease inhibitors (Complete tablet, Roche) and phosphatase inhibitor (mini tablet, 
ThermoFischer) using a glass bead homogenizer. The homogenate was centrifuged at 
1,000 G for 5 min at 4°C and the supernatant was collected. Homogenate was centrifuged 
again at 16,300 G for 30 mins at 4°C and the pellet was resuspended in RIPA buffer and 
vortexed. A protein assay was conducted to determine protein concentration of the 
samples. Samples were mixed with sample buffer (NuPage 4X sample buffer (Invitrogen, 
Grand Island, NY)) and heated to 95°C for 10 min. All samples were loaded onto a 4-
12% gradient gel at 40ug per sample/ per lane (NuPage Novex bis-tris, Invitrogen) and 
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run at 120 volts for 1-1.5 hrs. After removal from the cassette, the gel was incubated in 
transfer buffer for 30 mins at RT while shaking. Gels were transferred to PVDF 
membranes (Immobilin-FL, Millipore) using 90 mA current overnight at 4°C. 
Membranes were incubated in blocking buffer (LiCor Odyssey Blocking buffer 
(Invitrogen)) for 1 hr at room temperature, then incubated in primary antisera rabbit anti-
TrkB 1:1000 (Cell Signaling product #4603S) for 48 hours at 4°C. After rinsing with 
PBS containing 0.1% Tween-20, the membranes were incubated for 1 hr in secondary 
antisera (IR-Dye donkey anti-rabbit 800cw, LiCor). Membranes were then incubated in 
primary antisera for beta-actin 1:10,000 (Mouse anti-beta actin (Cell Signaling)) for 48 
hours at 4°C, followed by 1 hr incubation in secondary antisera (donkey anti-mouse 680 
rd, LiCor) at RT. After rinsing with PBS-Tween-20 the blot was placed in TBS until it 
was imaged using the LiCor Odyssey Imager. Quantification of the band signal was done 
using Image Studio Lite software. For each animal, TrkB signal band was normalized to 
actin band and this normalized signal was compared across groups. Sample size for all 
groups was n=5 except for female SNI group at day 3 where n=4.  
Statistical Analysis 
Graphical representations were prepared using GraphPad Prism (version 7; 
GraphPad Software, La Jolla, CA) while the data were analyzed using JMP Pro 15 (SAS 
Institute Inc., located at SAS Campus Drive, Cary, NC) obtained through the University 
of Minnesota. Data are expressed as the mean ± S.E.M. and all statistical analysis was 
considered significant at a ≤ 0.05.  BDNF and TrkB mRNA signal between experimental 




Confirmation of behavioral hypersensitivity 
In all the following experiments, tactile thresholds were measured using von Frey 
assay and the up-down method. All animals that received SNI surgeries had significantly 
lower tactile thresholds on the ipsilateral paw as compared to sham operated animals 
(Data not shown). 
Quantification of mRNA in DRG neurons and satellite cells 
BDNF mRNA expression in DRG neurons 
Representative images of ipsilateral L4 DRG from a male mouse at 3-days after 
nerve injury were collected using a confocal microscope at 20X magnification. A highly 
sensitive fluorescent in situ hybridization method allowed for visualization of BDNF 
mRNA in DRG. Higher punctate signal of BDNF mRNA in 20X image of DH of the 
spinal cord was observed (figure 1.1 b3) as compared to fluorescence observed in 
negative control probe treated DRG sections (figure 1.1 a3). Distribution of DRG neurons 
indicated uniform sampling of neurons across experimental groups in data sets collected 
at day 3 (figure 1.1 c), day 7 (figure 1.1 e), and day 28 (figure 1.1 g) post-SNI. Although 
the sampling was uniform across groups, the number of neurons vary across groups and 
therefore, the total area of DH occupied by BDNF mRNA signal was normalized to total 
area of neurons to obtain an average BDNF mRNA signal per micron area of neuron 
(figure 1.1 c, f, g). At day 3 post-SNI, an early timepoint after nerve injury, both male 
and female injured animals had increased BDNF mRNA signal in DRG neurons as 
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compared to their sham operated counterparts (male SNI (n=5) vs sham (n=5), p<0.001; 
female SNI (n=5) vs sham (n=5), p<0.05, Two-way ANOVA with Tukey’s post-hoc test, 
figure 1.1d).  No differences were detected in BDNF expression between any groups at 
day 7 post-SNI, a timepoint that represents the transitionary period between acute and 
chronic pain states (figure 1.1 f). At day 28 post-SNI, when chronic pain state has been 
established, SNI operated females had significantly lower average normalized BDNF 
expression in DRG compared to sham operated females (p<0.05, Two-way ANOVA with 
Tukey’s HSD, figure 1.1 h). 
TrkB mRNA expression in DRG neurons 
Representative images collected from a nerve injured male 28-days post-SNI at 
20X magnification show TrkB mRNA signal visualized using in situ hybridization in 
TrkB probe (figure 1.2 b3) treated and negative control treated (figure 1.2 a3) tissue 
sections. Distribution of neurons used for quantification of TrkB mRNA in DRG neurons 
showed uniform distribution across experimental groups at day 3 (figure 1.2 c), day 7 
(figure 1.2 e), and day 28 (figure 1.2 g) post-SNI. The average normalized TrkB mRNA 
signal was calculated by dividing the total area occupied by TrkB mRNA in DH by the 
sum of total area of all neurons to get the average TrkB mRNA signal per micron area of 
neuron (figure 1.2 d, f, h). At the acute (day 3, figure 1.2 d) and chronic stages post-SNI, 
no differences were observed between any of the groups, but sex differences and injury 
induced differences were detected during the transitionary phase (day 7 post-SNI). TrkB 
mRNA signal in DRG neurons from nerve injured females had lower mRNA signal as 
compared to injured males (male SNI vs female SNI, p<0.01, Two-way ANOVA with 
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Tukey’s HSD, figure 1.2 f) and sham operated females (female SNI vs sham, p<0.05, 
Two-way ANOVA with Tukey’s HSD, figure 1.2 f).  
BDNF mRNA in satellite cells of DRG 
The proportion of BDNF mRNA expressing and mRNA negative satellite cells 
indicated lower proportion of BDNF expressing satellite cells at day 28 post-SNI (figure 
1.3 g). To determine whether nerve injury altered the distribution of BDNF mRNA 
expression in neurons and satellite cells, the proportion of total BDNF signal found in 
satellite cell profiles was quantified and no differences were detected at any timepoint 
between any experimental groups (figure 1.3 b, e, h, Two-way ANOVA). The area of DH 
occupied by BDNF mRNA signal normalized to per micron area of satellite cells was 
used to obtain an average BDNF mRNA signal per micron area of satellite cell. At day 3 
post-SNI, male and female SNI animals had elevated BDNF mRNA in satellite cells as 
compared to their sham counterparts (male SNI vs sham, p<0.01, female SNI vs sham, 
p<0.05, Two-way ANOVA with Tukey’s HSD, figure 1.3 c). At day 28 post-SNI, female 
sham operated animals had higher amount of BDNF mRNA in satellite cells compared to 
sham operated males (p<0.05) or SNI operated females (p<0.01) Two-way ANOVA with 
Tukey’s HSD, figure 1.3 i). Overall, the BDNF signal at 28day timepoint seems lower 
than other timepoints, which could be an artifact of the immunohistochemical processing 
and variability associated with the tissue freezing, sectioning and staining procedures.  
TrkB mRNA expression in satellite cells of DRG 
The percentage of TrkB mRNA expressing and TrkB negative satellite cells are 
not vastly different at any of the timepoints. The proportion of TrkB mRNA in DRGs that 
is localized to satellite cells did not indicate any differences between experimental groups 
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at any timepoint post-SNI (figure 1.4 b, e, h). The average normalized TrkB signal 
(calculated by dividing total area of TrkB mRNA in satellite cells by total area of satellite 
cells in microns) was not different across groups at day 3 or 7 post-SNI (figure 1.4 c, f), 
however, at day 28 post-SNI, nerve injured female mice had lower TrkB mRNA signal in 
satellite cells of DRG as compared to that in sham-operated females (p<0.05, Two-way 
ANOVA with Tukey’s HSD, figure 1.4 i).  
Quantification in Spinal Dorsal Horn 
BDNF mRNA in DH of spinal cord 
Representative confocal images of the DH ipsilateral to nerve injury shows DAPI 
stained nuclei (figure 1.5 a1, b1), BDNF mRNA (figure 1.5 b2) or negative control probe 
(figure 1.5 a2), merged image was used to determine the degree of overlap between 
BDNF mRNA and nuclei (figure 1.5 a3, b3). Quantification of the total area of BDNF 
mRNA in DH (white outlined area) was split into two components, namely BDNF 
mRNA located in nuclei (DAPI stained profiles) and extra-nuclear mRNA (total area of 
BDNF – area of nuclear BDNF). At day 3 post-SNI, SNI females had greater area of 
BDNF mRNA in extra-nuclear portion compared to male SNI animals (p<0.05, Two-way 
ANOVA with Tukey’s HSD, figure 1.5 c). No other differences were detected at the 
other two timepoints (figure 1.5 d, e).  
TrkB mRNA in DH of spinal cord 
Representative images collected using a confocal microscope show DAPI stained 
nuclei (figure 1.6 a1, b1), TrkB mRNA (figure 1.6 b2) or negative control probe (figure 
1.6 a2), and merged images show TrkB mRNA overlap with nuclei (figure 1.6 a3, b3). 
The only differences observed in TrkB mRNA in spinal DH was at the transitionary phase 
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at day 7 post-SNI. At day 7 post-SNI, total area occupied by TrkB mRNA was lower in 
male SNI animals as compared to sham operated males (p<0.01) and injured females 
(p<0.05, Two-way ANOVA with Tukey’s HSD, figure 1.6 d). SNI males had lower TrkB 
mRNA in extra-nuclear cellular portions (p<0.01, Two-Way ANOVA with Tukey’s 
HSD, figure 1.6 d). The TrkB mRNA area restricted to nuclear profiles indicated higher 
TrkB mRNA in SNI operated males as compared to sham operated males (p<0.01), and 
higher nuclear TrkB mRNA in female SNI as compared to male SNI (p<0.05, Two-way 
ANOVA with Tukey’s HSD, figure 1.6 d).  
TrkB protein levels in spinal dorsal horn 
Relevant portions of the western blot membrane images are included along with 
the beta-actin control bands for each pair of comparisons. The fl-TrkB band appears 
approximately at 140-150 kDa as indicated by the protein ladder, while the truncated 
TrkB band appears around approximately at 95-100 kDa molecular weight. Samples from 
male and female animals are marked by colored arrows, and the quantification of the 
signal (normalized to actin) is included below the images of the membranes. At each 
timepoint 3-, 7-, and 28-day post-SNI, three comparisons were done, namely, male SNI 
vs female SNI (figure 1.7 a, d, g), male SNI vs male sham (figure 1.7 b, e, h), female SNI 
vs female sham (figure 1.7 c, f, i). Nerve injury did not increase protein levels of fl-TrkB 
receptor or truncated TrkB, however at day 3 (figure 1.7 a) and day 28 (figure 1.6 g) post-
SNI female SNI animals had significantly lower fl-TrkB and truncated TrkB receptor 
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Figure 1.1: Quantification of BDNF mRNA in DRG neurons at 3 days, 7 days, and 
28 days post-SNI.  
Representative confocal images of L4 DRG from a male mouse 3 days post-SNI 
ipsilateral to the injury (Negative control: a1-4, BDNF mRNA: b1-4). DAPI staining (a1, 
b1), non-specific staining with Cy2 conjugated donkey anti-mouse antibody to visualize 
DRG cell outlines (a2, b2), BDNF mRNA (b3) or control probe fluorescence (a3) Scale 
bar = 200um, 20X objective. Frequency distribution of neurons by size was consistent 
across experimental groups at the three timepoints tested (c, e, g). BDNF mRNA signal 
was obtained by normalizing total BDNF mRNA area for the unequal total neuronal 
surface area (d, f, h). At day 3 post-SNI, male and female nerve injured animals had 
significantly higher amount of BDNF mRNA in DRG neurons as compared to their sham 
counterparts (d, Two-Way ANOVA with Tukey’s HSD). Nerve injured females has 
significantly less BDNF mRNA in DRG neurons as compared to sham operated females 
at the 28-day post-SNI timepoint (h, Two-Way ANOVA with Tukey’s HSD). N=5 mice 
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Figure 1.2: Quantification of TrkB mRNA in DRG neurons at 3 days, 7 days, and 28 
days post-SNI. Representative images collected from SNI male 28 days post-SNI. DAPI 
(a1, b1), non-specific staining with Cy2 conjugated donkey anti-mouse antibody (a2, b2), 
TrkB mRNA (b3) or neg control probe (a3), and merged images (a4, b4). Scale bar = 
200um. 25X objective. Frequency distribution of neurons by size was consistent across 
experimental groups at the three timepoints tested (c, e, g). TrkB mRNA signal was 
obtained by normalizing total TrkB mRNA area for the unequal total neuronal surface 
area (d, f, g). At day 7 post-SNI timepoint, injured males and sham operated females had 
significantly higher TrkB mRNA in DRG neurons compared to nerve injured females (d, 
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Figure 1.3: Quantification of BDNF mRNA in DRG satellite cells. The number of 
BDNF mRNA positive satellite cells and those not expressing BDNF mRNA at days 3(a), 
7(d), and 28(g) post-SNI reveals that at day 28 timepoint, fewer satellite cells express 
BDNF mRNA as compared to the other timepoints (a, d, g). The proportion of total 
BDNF mRNA that is expressed in satellite cells was not different between any of the 
groups at any timepoint (b, e, h). The BDNF mRNA signal was also measured as average 
signal density per micron (um2) area of satellite cells (c, f, i). Interestingly, at day3 post-
SNI, Male and female injured animals had significantly higher BDNF mRNA signal in 
satellite cells as compared to their sham counterparts (c, Two-Way ANOVA with 
Tukey’s HSD). Additionally, at day28 post-SNI, injured females had significantly lower 
BDNF mRNA in satellite cells as compared to sham operated females, and sham females 
had higher BDNF mRNA compared to sham operated males (i, Two-way ANOVA with 
Tukey’s HSD). At each timepoint, each group included 5 animals. p<0.05*, p<0.01*
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Figure 1.4: Quantification of TrkB mRNA in satellite cells of DRG at days 3 (a, b, c), 
7 (d, e, f) and 28 (g, h, i) post-SNI. The proportion of TrkB mRNA expressing satellite 
cells was higher at days 3, and 7 but not at day 28 post-SNI (a, d, g). Across all 
experimental groups and timepoints, proportion of TrkB mRNA signal was not different 
between any groups (b, e, h). However, at day 28 post-SNI, nerve injured females had 
significantly lower TrkB expression density in satellite cells compared to sham operated 
females (i, Two-Way ANOVA, Tukey’s HSD). N=5 per group all timepoints. p<0.05*. 

















































































































































































































































































Day 3 post-SNI (a, b, c)
Day 7 post-SNI (d, e, f)




Figure 1.5: Quantification of BDNF mRNA in dorsal horn of spinal cord at days 3 
(c), 7 (d) and 28 (e) post-SNI. Representative images visualizing BDNF mRNA (b2) and 
negative control probe (a2) in DAPI stained nuclei (a1, b1) and extranuclear portion in 
dorsal horn (DH) spinal sections collected from SNI males at day 28 post-SNI (a, b). 
Scale bar = 200um, 20X objective. The total, extranuclear and nuclear portion of BDNF 
mRNA in DH ipsilateral to nerve injury or sham surgery at day 3 (c), day 7 (d), day 28 
(e). At day 3 post-SNI, female SNI animals have higher extra-nuclear BDNF mRNA (c, 












































































































Figure 1.6: Quantification of TrkB mRNA in dorsal horn of spinal cord ipsilateral 
to nerve injury at days 3(c), 7(d) and 28(e) post-SNI. Representative images collected 
from male SNI animals at day 3 post-SNI were used to visualize TrkB mRNA in DH (b2) 
and negative control probe (a2) and quantify mRNA signal in DAPI stained nuclei (a1, 
b1). Scale bar = 200um, 20X objective. The total amount of TrkB mRNA, the mRNA in 
nuclear and extra-nuclear portion of DH cells was quantified 3 days (c), 7 days (d) and 
28days post-SNI (e).  At day 7 post-SNI timepoint, male SNI animals had lower total and 
extranuclear TrkB mRNA compared to sham operated males (Two-way ANOVA with 
Tukey’s HSD, d). The total amount and nuclear proportion of TrkB mRNA was higher in 
SNI females compared to SNI males on day 7 post-SNI (Two-way ANOVA with 
Tukey’s HSD). Interestingly, SNI males had higher nuclear TrkB mRNA compared to 
sham males at day 7 post-SNI (d, Two-way ANOVA with Tukey’s HSD). N=5 animals 
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Figure 1.7: Western Blot analysis quantifying full-length TrkB receptor (fl-TrkB) 
and truncated form of TrkB in the dorsal horn of spinal cord at 3, 7, and 28 days 
post-SNI. Fl-TrkB is about 150kD, while the truncated form is more abundant and 
weighs about 100kD. Relevant portion of the western blots along with the beta-actin 
control lanes are marked with arrows indicating the male or female SNI animals (a, d, g). 
These data are quantified and visualized in the figures below the western blot images. At 
the 3-day and 28-day post-SNI timepoint there is a significantly higher amount of fl-TrkB 
and truncated TrkB in male injured animals as compared to injured females (a, g), 
whereas no sex differences were observed at the 7-day post-SNI timepoint. Interestingly, 
no differences were observed in the TrkB protein expression between injured and 
uninjured counterparts at any of the timepoints tested. Paired Student’s t-test. p<0.05*, 
p<0.0001. N=5 for all groups, except day 3 female SNI group (n=4).
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DISCUSSION 
mRNA detection in DRG and spinal cord 
Despite tremendous focus and interest in the role of BDNF-TrkB signaling in 
spinal neuroplasticity associated with nerve injury, very little is known regarding the 
changes in expression of BDNF and even smaller subset of the literature focuses on 
visualizing and quantifying TrkB. Early reports used in situ hybridization to demonstrate 
presence of BDNF mRNA in sensory neurons and antibodies that are either no longer 
available or unvalidated to detect BDNF immunoreactivity (-ir) to measure BDNF 
changes following nerve injuries (Michael et al., 1999; Fukuoka et al., 2001; Ha et al., 
2001; Obata et al., 2003; Geng et al., 2010; Terada et al., 2018). In our dataset, we 
observed a greater number of BDNF and TrkB positive neurons compared to prior 
reports. This could be explained by our use of RNAscope® technology which is highly 
sensitive and can detect a single mRNA strand. Therefore, it is possible that many 
neurons express low levels of BDNF or TrkB mRNA, but it does not participate in BDNF 
or TrkB protein synthesis or meaningfully contribute to BDNF-TrkB signaling. 
BDNF mRNA in DRG neurons and satellite cells 
Previous reports of BDNF mRNA in DRG neurons demonstrate higher BDNF 
mRNA levels in DRG neurons for up to 4 weeks after nerve axotomy, and even report a 
rightward shift in the neuronal distribution such that the frequency of larger neurons 
increased starting 4 days after axotomy (Michael et al., 1999). Another report of BDNF 
mRNA in DRG cells following chronic constriction injury (CCI) in rats show more 
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modest increase in BDNF mRNA at 14 days after injury (the only timepoint investigated) 
and did not report any shifts in BDNF expressing neuronal distribution (Obata et al., 
2003)  Yet another report measuring BDNF mRNA in rat DRG after spinal nerve ligation 
model of nerve injury, reported an increase in BDNF mRNA as early as day 4 after injury 
that remained elevated up to 4 weeks when the study ended (Fukuoka et al., 2001) These 
studies collectively indicate injury-, time-, and region-specific changes in BDNF mRNA, 
however, none of these studies measure changes at the DRG and spinal level or 
investigate its presence in different cell types or sexes.  
Data presented in this chapter indicates SNI induced increase in BDNF mRNA in 
DRG neurons at day 3 post-SNI timepoint in males and females (figure 1.1d). 
Distribution of BDNF expressing neurons resembles that of general neuronal distribution 
included in figure 1.1 (c, e, g) since over 90% of DRG neurons express BDNF mRNA. 
The distributions across experimental groups were not different and no rightward shift 
was observed in our data set. The mismatch between results in this chapter and previous 
reports can be explained by the difference in nerve injury model and a more sensitive 
mRNA detection method. However, when BDNF mRNA area is normalized to the 
neuronal area, we observed an injury induced increase suggesting an overall increase in 
BDNF mRNA after injury. Interestingly, our experiments did not show significant 
elevation in BDNF mRNA in DRG neurons at days 7 or day 28 post-SNI, but nerve 
injured females had lower BDNF mRNA in DRG neurons as compared to sham operated 
females at day 28. These results indicate a sex-, time-, and injury-dependent effects on 
BDNF mRNA expression. Therefore, during early stages of nerve injury, male and 
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female systems respond similarly by increasing BDNF expression in DRG neurons 
(figure 1.1 d), whereas during the chronic pain stage at day 28 post-SNI, nerve injured 
females downregulate BDNF expression compared to sham females (figure 1.1 h) 
suggesting a compensatory decrease in females after injury. 
BDNF mRNA in satellite cells 
Although the role of satellite cells in modulating DRG neuron activity has been 
appreciated, its participation in BDNF-TrkB signaling in DRG is unclear. Satellite glial 
cells closely associate with DRG neurons and engage in increased signaling to maintain 
neuronal excitability (Ji et al., 2013; Milosavljević et al., 2020). Satellite cells are known 
to release ATP, inflammatory factors, cytokines, and chemokines that can maintain an 
inflammatory state at the DRG level thus contributing to the maintenance of the 
neuropathic pain state (Scholz and Woolf, 2007; Ji et al., 2013; Milosavljević et al., 
2020). Since not much is known about BDNF and TrkB expression in satellite cells, we 
evaluated the proportion of satellite cells that express BDNF mRNA, and at day 3 and 7 
post-SNI, about half of all satellite cells expressed BDNF. At day 28, the overall signal 
was lower and therefore the proportion of BDNF positive satellite cells was also lower. 
The increased BDNF mRNA in injured males and females at day 3 post-SNI compared to 
shams match those seen in DRG neurons, indicating that similar kinds of changes due to 
injury occur in DRG neurons and satellite cells. Furthermore, the BDNF mRNA signal 
pattern at day 28 post-SNI is like that seen in neurons, such that female SNI animals had 
lower BDNF mRNA compared to sham females (figure 1.3 i). Interestingly, female sham 
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group had higher BDNF mRNA expression compared to sham males which points to sex- 
and time-dependent reversal of BDNF mRNA expression.  
TrkB mRNA expression in DRG neurons and satellite cells 
The limited information about TrkB expression in DRG usually extends to 
demonstrating TrkB expression in DRG neurons (Foster et al., 1994; Yan et al., 1997). 
Here, we characterized the TrkB expression pattern in DRG neurons. We found that 
during the transitionary period from acute to chronic pain state, TrkB expression in 
injured females was lower than males which may either indicate the lack of TrkB 
involvement in this transition, or a compensatory decrease to reach homeostasis.  
The proportion of TrkB positive to TrkB negative satellite cells, or the proportion 
of total TrkB mRNA localized to satellite cells was not affected by injury or sex-
dependent variables. The only difference detected was at day 28 post-SNI where injured 
females had lower TrkB expression compared to sham, which matches the pattern of 
BDNF mRNA expression. This may indicate that TrkB is not a major player in 
maintaining neuropathic pain state in females or it might suggest that once chronic pain 
state is established, most signaling factors are downregulated.  
BDNF and TrkB expression in spinal cord 
BDNF expression in spinal dorsal horn ipsilateral to the nerve injury is not significantly 
different between experimental groups. Interestingly, about half of the total BDNF 
mRNA signal was located outside of nuclear profiles. Typical quantification methods 
limit mRNA quantification to nuclear region, however, by doing so a significant portion 
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of mRNA signal is missed. At day 3 post-SNI, female SNI mice had higher BDNF 
mRNA in extra-nuclear portion compared to male injured animals. The significance or 
difference between the role of mRNA in nuclear profiles vs cytoplasm is unclear. Unlike 
BDNF expression in DH, sex- and injury- dependent effects on TrkB mRNA are detected 
at day 7 post-SNI, wherein injured males had lower TrkB expression compared to sham 
operated males and injured females. Similar effects were noticeable in the extra-nuclear 
and nuclear portions. These data largely match those seen in DRG cells in that TrkB 
expression seems to change at the day 7 timepoint. It may mean that TrkB receptor 
activity is crucial for the transitioning of acute to chronic pain. Collectively, these results 
suggest that injury induced changes in BDNF and TrkB expression is altered in regions 
initially affected by peripheral nerve injury.  
TrkB protein expression in spinal cord 
 Immunohistochemistry for TrkB protein has proven difficult due to the absence of 
validated and reliable antibodies, however, most experiments that involve measuring fl-
TrkB or truncated TrkB use western blot assays (Yajima et al., 2002; Geng et al., 2010).  
Unlike these reports, we did not find injury induced increase in fl-TrkB or truncated TrkB 
protein levels in DH in males or females. It is possible that the amount of detectable of fl-
TrkB is low which may mask any subtle effects between groups. Interestingly, at early 
and late timepoint after nerve injury, injured male mice had higher fl-TrkB and truncated 
TrkB protein levels in DH as compared to that of injured females (figure 1.7 a,d). This 
suggests an underlying sex-difference such that the expression of TrkB protein levels is 
 45 
lower in females at baseline or injury induced increase in females is lower than that seen 
in males.  
Collectively these data point to sex-, region-, and times-dependent changes in 
BDNF and TrkB mRNA and protein levels in areas of the pathway that are initially 
affected by nerve injury. We noticed an increase in BDNF expression in DRG neurons 
and satellite cells at day 3 post-SNI, and a decreased BDNF expression by 28days post-
SNI, however, TrkB expression is only reduced in injured females at day 7 when the pain 
state transitions from acute to chronic. In contrast to the TrkB mRNA expression in DRG, 
nerve injured females have increased TrkB expression in SC as compared to injured 
males. The exact role of these receptors expressed in different components of the pain 
pathway in a sex-, time- and region-specific manner will greatly advance our knowledge 
about the differences and commonalities in BDNF-TrkB signaling in different models of 
pain and the two sexes.  
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CHAPTER 2: FUNCTIONAL ROLE OF TRKB ACTIVATON IN SNI INDUCED 
HYPERSENSITIVITY 
INTRODUCTION 
BDNF signaling contributes to spinal neuroplasticity underlying central 
sensitization (Pezet et al., 2002; Marcol et al., 2007; Merighi et al., 2008; Smith, 2014). 
Many signaling cascades are involved in this process which collectively modifies the 
spinal nociceptive circuitry to amplify noxious and innocuous stimuli evoked sensory 
perception (Bramham and Messaoudi, 2005; Coull et al., 2005; Geng et al., 2010; Zhang 
et al., 2011a; Zhou et al., 2011; Chen et al., 2014b; Khan and Smith, 2015; Hildebrand et 
al., 2016; Kitayama et al., 2016; Li et al., 2017; Wang et al., 2019). These changes due to 
BDNF are thought to occur via activation of TrkB receptor which is the high affinity 
receptor for BDNF. The NTRK2 gene encodes for three distinct forms of the TrkB 
receptor (Middlemas et al., 1991; Minichiello, 2009). The full-length receptor (fl-TrkB) 
often referred to as gp145TrkB consists of 821 amino acid sequence and has an 
intracellular kinase domain that autocatalyzes upon ligand binding (Middlemas et al., 
1991; Minichiello, 2009). The two alternatively splices truncated forms - T1 (often 
referred to as gp45TrkB) and the less well-known and uncharacterized T2 share the 
transmembrane and extra-cellular sequence with fl-TrkB, however the T1 and T2 forms 
have 11 and 9, respectively, unique intracellular amino acid sequences and lack 
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intracellular kinase domains and this cannot engage in canonical downstream signaling 
cascades.  
Since intracellular signaling from BDNF is thought to be carried out because of 
fl-TrkB phosphorylation (pTrkB), the truncated forms were thought to lack the ability to 
induce intracellular signaling. Some believed the truncated TrkB receptors hinder TrkB 
activity by sequestering BDNF thus inhibiting or lowering fl-TrkB activation and the 
subsequent downstream signaling (Middlemas et al., 1991; Squinto et al., 1991; Barbacid, 
1994; Lu et al., 2005; Reichardt, 2006; Mitre et al., 2016). More recent evidence indicates 
that T1 TrkB can induce intracellular calcium signaling in astrocytes via an unknown 
mechanism (Cao et al., 2020). And the consequences of those downstream signaling 
cascades in contrast to the signaling initiated by fl-TrkB activity is undetermined.  
 Major roadblock in investigating the extent and anatomical specificity of TrkB 
activity is the lack of methods to visualize or measure TrkB activity while preserving 
anatomical information. Usually, TrkB activation is indirectly measured by evaluating 
processes and markers downstream of TrkB phosphorylation (Yajima et al., 2002; Coull 
et al., 2005; Geng et al., 2010; Zhou et al., 2011; Chen et al., 2014b; Hildebrand et al., 
2016; Li et al., 2017; Wang et al., 2019). These types of analyses can be used to assess 
the overall consequences of TrkB signaling at large, however, they do not provide 
information regarding the spatial extent of context dependent TrkB activity. Furthermore, 
activity of downstream factors is often used to construe the effect of TrkB activation of 
signaling factors or substrates in the same cell or region, however such information is 
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obtained indirectly and does not provide the necessary context for TrkB activity in injury 
induced neuroplasticity (Geng et al., 2010; Hildebrand et al., 2016; Li et al., 2017).  
 Inhibition of TrkB activation is another avenue of investigation to study the causal 
role of TrkB in BDNF-TrkB signaling mediated changes. However, this goal too is 
hindered by the lack of specific tools to block TrkB activity. For instance, the drug 
previously widely used as a TrkB inhibitor, K252a, later was found to block most Trk 
receptors along with intracellular kinases including PKC (Buchholz et al., 2018; León et 
al., 2020). Other methods like BDNF sequestration or deletion of cell types assumed to 
release BDNF (Mannion et al., 1999; Raghavendra et al., 2003; Ledeboer et al., 2005; 
Xiaodi et al., 2010; Zhang et al., 2011b, 2011a; Zhou et al., 2011; Li et al., 2017) 
following increased neuronal activity are also commonly used and pose a problem 
regarding the specificity of these tools to alter TrkB activity.  
The issues in data interpretation stemming from indirect results is compounded by 
the lack of information in related domains, for instance, sex differences in BDNF-TrkB 
signaling have been broadly advertised and accepted. However, the experiments that gave 
rise to these speculations primarily targeted microglial function and manipulated 
microglial activity without confirming the mechanistic consequences of those 
manipulations (Zhou et al., 2011; Sorge et al., 2015). As a result, the behavioral sex-
differences that were observed were prematurely attributed to differences in BDNF-TrkB 
signaling. Another study generated a pharmacogenetic mutant line in which the 
endogenous TrkB receptor is replaced with a modified TrkB receptor which can be 
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manipulated using a drug specifically designed for these receptors (Wang et al., 2009). In 
this study male and female mice were tested but the results did not specify sample sizes 
or any observed sex-differences. It is unclear if they did not detect any sex-differences or 
if they did not look for them. Since majority of the studies in this field only used male 
subjects, the dearth of information regarding the expression and function of BDNF, TrkB, 
and downstream factors in females sparked interest in sex-differences in the BDNF-TrkB 
signaling pathway. Experiments in this chapter were designed to evaluate if TrkB 
activation is absent in SNI operated female mice or whether TrkB is functionally required 
for the maintenance of behavioral hypersensitivity.  
Given these challenges in studying the degree and spatial limits of TrkB 
activation due to peripheral nerve injury, we validated an antibody directed against the 
phosphorylated form of TrkB (pTrkB) and quantified changes in TrkB activity at various 
timepoints after injury to assess sex-differences in injury-induced TrkB activation. Next, 
we employed a novel small molecule TrkB inhibiting drug, ANA-12, that was initially 
characterized in hippocampal learning and memory paradigm (Cazorla et al., 2011). 
Using this TrkB antagonist, we conducted experiments to test whether ANA-12 has time- 
and sex-dependent effects on behavioral hypersensitivity. Finally, additional control 
studies were performed to evaluate and understand behavioral and biological side-effects 
arising from the vehicle used in behavioral experiments. 
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MATERIALS AND METHODS 
Animals 
All experiments were conducted in compliance with National Institutes of Health 
Guide for Care and Use of Laboratory Animals and approved by the University of 
Minnesota Institutional Animal Care and Use Committee. Male and female ICR-CD1 
WT mice (20-40 g) were used for all the following experiments. Animals were group 
house 4 males per cage, and 5 females per cage in a temperate and humidity-controlled 
SPF facility on a 12-hour light/dark cycle. The animals had free access to food and water. 
Spared Nerve Injury (SNI) 
This procedure is described in more detail in Chapter 2. Briefly, while under deep 
anesthesia, the thigh muscle on the left side was exposed and bluntly dissected to 
visualize the sural nerve. Two of the branches, tibial and common peroneal, were ligated 
with 5.0 silk suture and about 2mm portion of the nerve was cut and removed to prevent 
nerve regeneration. Muscle was closed with 4-0 monofilament absorbable suture and the 
overlaying skin was stapled. Animals were monitored for 3 days post-operatively.  
Behavioral hypersensitivity assay 
A detailed description of the Von Frey assay is described in methods section of 
Chapter 2 as well as in (Chaplan et al., 1994) and (Dixon, 2012). A 50% threshold 
calculation is used to determine withdrawal thresholds by applying a series of synthetic 
monofilaments to the lateral portion of the mouse hand paw. For all groups, male and 
female animals were tested separately to avoid any confounds due to pheromonal effects. 
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Males and females were either tested on different days or the room was thoroughly 
cleaned if the two were tested on the same day in separate sessions.  
Tissue preparation and sections 
Following behavioral assessment, mice were deeply anesthetized with isoflurane 
and perfused via the heart with calcium-free Tyrode’s solution (in mM: 116 NaCl, 5.4 
KCl, 1.6 MgCl2·6H20, 0.4 MgSO4·7H2O, 1.4 NaH2PO4, 5.6 glucose, and 26 
Na2HCO3) followed by fixative (4% paraformaldehyde and 0.2% picric acid in 0.1 M 
phosphate buffer, pH 6.9). The spinal cord or brains (for hippocampal sections) were 
removed, cryoprotected in 10% sucrose overnight, covered with OCT and frozen using 
liquid CO2, and cryostat-sectioned into 14 μm sections that were slide-mounted. Sections 
were preabsorbed in T/T/T buffer (TBS containing 0.2% Triton-X 100 and 0.2% Tween 
20) for 30 min followed by incubation with a rabbit anti-pTrkB (Y816) 1:500 (Millipore 
Sigma-Aldrich ABN1381) diluted in T/T/T overnight at 4°C in a humidified chamber. 
Tissue sections were then washed 3X 10 mins each in TBS, incubated with a secondary 
antibody solution containing Cy3 Donkey anti-Rabbit 1:300 (Jackson Labs) in T/T/T for 
1hr at room temperature. Slides were then washed in TBS 3X10 mins each and cover 
slipped with FluorSaveTM (Millipore 345789). Sections were allowed to dry and stored at 
room temperature until being imaged.
Phosphatase Treatment 
Slide mounted tissue sections (mentioned above) were treated with Lambda 
Protein Phosphatase (LPP) (BioLabs P0753S). A NEB buffer solution was prepared by 
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adding 1ml of 10XNEB and 1ml of MnCl2 to 10mls of dH2O and aliquoted and stored at 
-80° C. Each tissue section was treated 100ul/slide with LPP containing or LPP lacking 
NEB
buffer. To prepare the LPP solution, 20ul of LPP stock was added to 350ul of NEB 
buffer, while for control slides were treated with NEB buffer alone. Tissue sections were 
circled with hydrophobic pen and treated with either LPP solution or NEB solution 
overnight at 37° C in a humidified chamber for 8 hours. Sections were washed with TBS 
3X10 mins each and IHC protocol for pTrkB staining was conducted as described above.
Western Blot Analysis 
SNI male and female mouse spinal cords were harvested by hydraulic extrusion 
28days post-SNI. Hippocampal tissue was collected by rapidly dissecting and extracting 
brains from mice euthanized at day 28 post-SNI. The lumbar enlargement was isolated 
and divided into ipsi- and contralateral halves for tissue analysis. Tissue samples were 
flash frozen using liquid nitrogen and stored at -20O C. Tissues were allowed to thaw on 
ice before being homogenized in RIPA solubilization buffer (Phosphate buffered Saline 
(PBS) with 0.1% IPEGAL (ICN Biomedicals), 12mM sodium deoxycholate, and 
0.1%SDS) containing protease inhibitors (Complete tablet, Roche) and phosphatase 
inhibitor (mini tablet, ThermoFischer) using a glass bead homogenizer. The homogenate 
was centrifuged at 1,000 G for 5 min at 4°C and the supernatant was collected. 
Homogenate was centrifuged again at 16,300 G for 30 mins at 4°C and the pellet was 
resuspended in RIPA buffer and vortexed. A protein assay was conducted to determine 
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protein concentration of the samples. Samples were mixed with sample buffer (NuPage 
4X sample buffer (Invitrogen, Grand Island, NY)) and heated to 95°C for 10 min. All 
samples were loaded onto a 4-12% gradient gel at 40ug per sample/ per lane (NuPage 
Novex bis-tris, Invitrogen) and run at 120 volts for 1-1.5 hrs. After removal from the 
cassette, the gel was incubated in transfer buffer for 30 mins at RT while shaking. Gels 
were transferred to PVDF membranes (Immobilin-FL, Millipore) using 90 mA current 
overnight at 4°C. Membranes were incubated in blocking buffer (LiCor Odyssey 
Blocking buffer (Invitrogen)) for 1 hr at room temperature, then incubated in primary 
antisera rabbit anti-pTrkB (Y816) 1:500 (Millipore Sigma-Aldrich ABN1381 for 48 
hours at 4°C. After rinsing with PBS containing 0.1% Tween-20, the membranes were 
incubated for 1 hr in secondary antisera (IR-Dye donkey anti-rabbit 800cw, LiCor). 
Membranes were then incubated in primary antisera for beta-actin 1:10,000 (Mouse anti-
beta actin (Cell Signaling)) for 48 hours at 4°C, followed by 1 hr incubation in secondary 
antisera (donkey anti-mouse 680rd, LiCor) at RT. After rinsing with PBS-Tween-20 the 
blot was placed in TBS until it was imaged using the LiCor Odyssey Imager. 
Quantification of the band signal was done using Image Studio Lite software. Results 
normalized to actin were averaged within group n=4 or n=5 per group.  
Imaging and Quantification 
A Nikon A1RMP confocal microscope (25X objective, 1.1 NA) at the University 
of Minnesota Imaging Center was used to obtain images of tissue sections. Imaging 
parameters were set using negative controls (NEB treated controls for LPP treated 
sections, Sham control for SNI vs sham comparisons) to set the lower parameters and the 
sections with highest fluorescence was used to determine the maximum exposure settings 
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to avoid saturation. All images in a single data set were collected on the same day at the 
same microscope settings. Tissue blocks for the purposes of sectioning were grouped by 
the duration after SNI, therefore, data from the three timepoints cannot be compared 
across time.  Three images from evenly spaced tissue sections of L3 and L4 region of 
spinal cord were collected. All quantification was conducted using FIJI software by an 
experimenter blinded to the treatment conditions and groupings. An ROI was manually 
drawn to outline the dorsal horn of spinal cord, and minimum threshold was manually 
selected for each tissue section. The Area of pTrkB-ir (denoted as %area of pTrkB-ir) as 
a function of ROI size were obtained and used to compare pTrkB-ir in different groups. 
For all quantification in Fig 3.1-3.5, only ipsilateral dorsal horn images were collected 
from three evenly spaced spinal sections and averaged to get a single value per animal. 
The data presented in Fig 3.6 was collected from naïve animals in which we do not 
expect any laterality of effect. Therefore, bilateral images of dorsal horn were collected 
from three evenly spaced spinal sections and a single value per animal was obtained for 
further analysis.  
TrkB inhibitor 
ANA-12 is a novel small molecule drug that was previously described for its 
antidepressant and anxiolytic properties in a mouse model (Cazorla et al., 2011). A 
10mM stock of ANA-12 with DMSO were aliquoted and frozen at -20°C. For injections, 
200uM solution was prepared by diluting the 10mM ANA-12 stock into a 1:1.5 diluent of 
PEG300: sterile saline. Vehicle control solution was made by substituting ANA-12 stock 
with DMSO in 1:1.5 PEG300: sterile saline.  5ul of the 200uM solution (1nmol) of ANA-
12 was injected intrathecally into each animal as described previously (Mestre et al., 
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1994).  ANA-12 solution for intraperitoneal injections was made by dissolving the 10mM 
DMSO containing stock in sterile PBS at 5mg/ml solution and animals were injected 
0.5mg/kg per mouse. Vehicle for experiments in which ANA-12 was injected 
intraperitoneally replaces ANA-12 with DMSO. 
Statistical Analysis 
All datasets were assessed for normality to determine whether a parametric or 
non-parametric test was appropriate. Student’s t test, One-Way ANOVA or Two-Way 
ANOVA were run using JMP Pro 15 licensed through University of Minnesota. Data are 




Validating antibody in hippocampal tissue 
To determine if the pTrkB antibody detects a protein of the correct molecular 
weight, we performed western blot assay on hippocampal tissue collected from male and 
female SNI mice 28 days after surgeries and were able to visualize a band around 
140kDa which likely corresponds to the phosphorylated fl-TrkB receptor (figure 2.1 a). 
Hippocampal tissue was used for Western blots because of the well-defined protocols for 
tissue processing for pTrkB visualization. Since the original report of ANA-12 inhibition 
of TrkB phosphorylation used Western blot assay to confirm reduction in TrkB 
phosphorylation in hippocampal tissue, we followed the same drug dosage (0.5mg/kg) 
and timeline (2 hrs post drug) to collect hippocampal tissue for histology. Representative 
images of pTrkB-ir in hippocampus tissue sections from vehicle (figure 2.1 b1) and 
ANA-12 (figure 2.1 b2) treated animals showed a significant decrease in pTrkB-ir in 
dentate gyrus of ANA-12 injected mice (p<0.05, Student’s t test, figure 2.1 c).  
Detecting a phosphorylated protein in spinal DH 
To verify that the antibody detects a phosphorylated protein, tissue sections 
collected from male SNI operated animals 3 days post-SNI and were treated with lambda 
protein phosphatase (LPP) to dephosphorylate protein residues, or with a control NEB 
solution that does not have any dephosphorylating activity. Representative images show 
dorsal horn of spinal cord from animals 3 days after SNI (figure 2.2 a, b, c). Ipsilateral 
DH treated with NEB (vehicle control) has higher fluorescence associated with pTrkB-ir, 
as compared to contralateral DH treated with NEB (figure 2.2 a, b). Ipsilateral DH tissue 
sections were incubated in LPP solution or NEB overnight at 37°C in a humidified 
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chamber. Our quantification indicates that SNI increased pTrkB-ir in DH ipsilateral to 
nerve injury as compared to the contralateral DH (p<0.00001 One-Way ANOVA with 
Tukey’s multiple comparison test figure 2.2 d), and LPP treatment significantly reduced 
pTrkB-ir as compared to the ipsilateral DH (p<0.00001) and even the contralateral DH of 
sections treated with NEB (p<0.05 figure 2.2 d).  
TrkB activity in spinal DH after nerve injury 
To determine if the pTrkB signal is increased following nerve injury, pTrkB-ir in 
ipsilateral dorsal horn of male and female mice after SNI or sham procedures. 
Representative images collected at day 3 post-SNI showed pTrkB-ir in ipsilateral DH 
(figure 2.3 b), but not the contralateral dorsal horn in SNI operated male (data not 
shown), while ipsilateral DH of sham operated male had lower pTrkB-ir (figure 2.3 a).  
Behavioral testing was conducted to screen for behavioral sex-differences. Baseline 
tactile thresholds were measured prior to surgical procedures, and 3 days after the surgery 
when behavioral hypersensitivity develops in this model. Both male and female SNI 
animals had significantly lower 50% withdrawal thresholds as compared to sham 
operated controls indicating that the injured animals were hypersensitive on the side of 
injury (p<0.01, p<0.0001, Two-way repeated measures ANOVA with Tukey’s post-hoc 
comparison, figure 2.3 c). The quantification of pTrkB-ir in DH of spinal cord revealed 
increased pTrkB-ir in ipsilateral DH in nerve injured males and females as compared to 
their sham operated counterparts (p<0.0001, Two-way ANOVA with Tukey’s post-hoc 
test, figure 2.3 d). SNI-operated male and female mice had comparable amount of pTrkB-
ir in ipsilateral DH. However, sham females had significantly higher amount of pTrkB as 
compared to sham males, suggesting that females have higher amount of baseline TrkB 
 58 
activity or the sham surgical procedure results in greater inflammatory reaction in female 
sham mice as compared to sham males (p<0.001, Two-Way ANOVA with Tukey’s post-
hoc test). 
TrkB activity in males at multiple timepoints after injury 
 Since we did not detect any sex differences in the SNI induced increase in pTrkB-
ir between male and female nerve injured animals, we performed additional experiments 
to compare SNI induced pTrkB-ir at 3 different timepoints to test whether sex-differences 
are time-dependent. At all three timepoints, male and female mice were hypersensitive in 
the paw on the ipsilateral side of injury and no sex-differences were detected in the level 
of hypersensitivity (figure 2.4 a, c, e). Additionally, pTrkB-ir was similarly increased in 
both sexes at 3 days (b), 7 days (d), 28 days (f) after nerve injury (Student’s t test, figure 
2.4 b, d, f). Therefore, we did not detect sex-differences in the SNI induced behavioral 
hypersensitivity or increase in pTrkB-ir.  
Functional role of TrkB activity in male and female mice 
 Although female mice had a similar degree of TrkB activation in DH after SNI, 
the functional role of that activity was undetermined. We hypothesized that in female 
mice, TrkB activity does not functionally contribute to the SNI induced behavioral 
hypersensitivity as it does in male mice. To test this hypothesis, we injected male and 
female SNI operated animals at multiple timepoints after injury and the animals were 
injected with a single 1nM dose of ANA-12 (i.t.) or vehicle once at the beginning of test 
days. All animals were baselined before SNI surgeries, and all animals were 
hypersensitive on the injured side when tested at day 3 post-SNI and remained 
hypersensitive for the duration of the study (figure 2.5). Interestingly, ANA-12 had a 
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modest but significant anti-hyperalgesic effect on days 7, 14 and 28 post-SNI (Repeated 
measures Two-way ANOVA with Tukey’s HSD for multiple comparisons, p values 
indicated by asterisks on graphs indicate significant difference from control group at the 
matching timepoint, figure 2.5 a). Unexpectedly, ANA-12 did not significantly reduce 
hypersensitivity in female mice, and in fact, vehicle treatment had a small anti-
hyperalgesic effect in females (Repeated measures Two-way ANOVA with Tukey’s 
multiple comparisons, figure 2.5 b). Collectively, these data indicate that the effect of 
ANA-12 on behavior is sex-dependent.  
Efficacy of ANA-12 in spinal TrkB inhibition in male and female mice 
 The sex-differences in the behavioral effect of TrkB inhibitor, ANA-12, in female 
mice gave rise to two possible explanations for the sex difference – first, TrkB activity 
does not contribute to SNI induced hypersensitivity, or second, ANA-12 acts differently 
in male and female animals. To determine which of these possibilities is the likely 
explanation, we collected DH tissues from animals at 2 hrs post-drug at day 7 post-SNI 
(day and time post-injury, and post-drug with maximal drug effect) after ANA-12 or 
vehicle treatment. Although the behavioral experiment did not show significant reduction 
in hypersensitivity in males, the pattern of ANA-12 reducing hypersensitivity in males 
and increasing hypersensitivity in females as compared to their sham counterparts 
observed previously was maintained (figure 2.6 a). Immunohistochemical assessment of 
degree of TrkB inhibition in male and female SNI mice yielded surprising results (figure 
2.8 b). ANA-12 treatment which in another dataset significantly reduced behavioral 
hypersensitivity, had higher pTrkB-ir as compared to vehicle treated SNI males 
(Student’s t test, p<0.05, figure 2.6 b). In contrast, ANA-12 treatment previously did not 
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have a significant anti-hyperalgesic effect on SNI induced hypersensitivity, the pTrkB-ir 
in ANA-12 treated female cords was lower compared to their vehicle treated counterpart 
(Student’s t test, p<0.05, figure 2.6 b). Taken together, the results presented here suggests 
that TrkB activity negatively regulates SNI induced hypersensitivity, and that the drug 
effects were sex dependent.  
ANA-12 effects on naïve male and female animals  
Since we detected some effects of vehicle on SNI females as compared to ANA-
12 treated SNI females, we conducted additional experiments to test the effects of ANA-
12 and vehicle on tactile sensitivity and TrkB activity in naïve mice. Naïve male and 
female animals were injected with ANA-12, vehicle, or saline intrathecally, and tested at 
2 and 4 hours after injections. ANA-12 or vehicle did not influence tactile thresholds in 
naïve males and females as compared to saline injected control counterparts (figure 2.7 
a). We then collected spinal tissue at 5 hours post-drug injections to quantify pTrkB-ir in 
different groups. We detected significant main effect of sex (p<0.0001) as well as 
treatment (p<0.0060) without significant interaction between the two (p=0.27) in a Two-
Way ANOVA. Multiple comparisons test revealed that saline injected naïve female mice 
had higher pTrkB-ir as compared to saline injected naïve males, suggesting that females 
normally may have higher baseline TrkB activity which is consistent with the data from 
3days post-SNI where sham operated females had higher pTrkB-ir in ipsilateral DH 
compared to that of the male sham operated mouse (Two-way ANOVA with Tukey’s 
HSD p<0.05, figure 2.7 b). This sex difference is maintained in ANA-12 injected groups 
where female ANA-12 injected animals had higher proportion of pTrkB-ir as compared 
to their male counterparts (p<0.001). Although the decreased pTrkB-ir in vehicle treated 
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male and female mice was not significantly difference from saline controls, it was 
sufficient to mask the latent sex differences in pTrkB-ir. Finally, in naïve females, vehicle 
injected females had significantly less pTrkB-ir as compared to ANA-12 treated females, 
neither of which were significantly difference from saline injected females. On the other 
hand, none of the treatments significantly altered pTrkB-ir in males, which might suggest 
that the female CNS is more susceptible to the effects of DMSO, PEG300, and ANA-12 





Figure 2.1: Validation of antibody in hippocampal tissue. Western blot assay of 
hippocampal tissue collected from male SNI and female SNI mice 28-days post-SNI 
showed a bright band with molecular weight of ~140kDa which corresponds to the 
weight of the full-length TrkB (150kDa) receptor (a). Confocal images of dentate gyrus 
of hippocampus collected from TrkB inhibitor, ANA-12 (i.p), injected male mice 3 days 
post-SNI had significantly lower pTrkB-ir (b2) as compared to hippocampal tissue from 
vehicle treated mice (b1). Quantification of pTrkB-ir in dentate gyrus indicates 
significantly lower amount of immunoreactivity in ANA-12 treated animals (b2) as 
compared to vehicle treated controls (c). Student’s t test. p<0.05*. N=6 animals per group 












































































Figure 2.2: Validating antibody directed against phosphorylated TrkB in spinal 
cord after nerve injury. Confocal images of ipsilateral (a, c) and contralateral (b) DH of 
SC sections treated with a phosphatase (LPP) (c) or control buffer (NEB, MnCl2, 
DMSO) vehicle (a, b). Ipsilateral dorsal horn of SNI males has visible pTrkB-ir (a) 
compared to the contralateral dorsal horn (b). LPP treatment of spinal sections 
significantly reduces pTrkB-ir in dorsal horn (c), even lower than staining in contralateral 
dorsal horn (d). One way ANOVA, with Tukey’s post-hoc test. p<0.05*, p<0.0001*** 
Scale bar = 200um. N=6, tissues from same animals used for the treatments and 
comparison. 
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Figure 2.3: Quantification of TrkB phosphorylation at day 3-post SNI. A confocal 
image of the left dorsal horn from a sham operated male (a) and nerve inured male (b) 
immunostained for phosphorylated form of TrkB (p-TrkB) is visualized. scale 
bar=200um, 20X magnification. The behavioral data from Von Frey assay shows that 
both male and female SNI operated animals were significantly more hypersensitive as 
compared to their sham operated counterparts (c). Consequently, male and female SNI 
operated animals had significantly higher pTrkB immunoreactivity at day 3 post-SNI as 
compared to their sham counterparts (d). A significantly higher pTrkB-ir was observed in 
sham operated females as compared to males at day 3 post-SNI (d). Two-way ANOVA 
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Figure 2.4: SNI induced TrkB activation in male and female mice at day 3 (a, b), 
day 7 (c, d), and day 28 (e, f) after injury. 
We did not detect any behavioral sex differences in tactile thresholds at baseline or any 
timepoint after injury (a, c, e). Correspondingly, Nerve injured male and female mice had 
similar levels of pTrkB-ir in the ipsilateral dorsal horn at all time-points (b, d, f). Two-
way repeated measures ANOVA for behavioral analysis, Student’s t test or pTrkB-ir. 
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Figure 2.5: Repeated injections of ANA-12 (i.t.) in male and female nerve injured 
mice. Male (a) and female (b) SNI mice were baselined before SNI and at days 3, 7, 14, 
and 28 post-SNI. On days post-SNI, tactile thresholds were tested prior to drug injections, 
and at 2hrs, 4hrs, and 6hrs after ANA-12(i.t.) or vehicle (i.t.). ANA-12 treated SNI males 
had significantly higher tactile thresholds on day 7 (4 and 6 hrs after drug), day 14 (6 hrs 
after drug), day 28 (4 and 6 hrs post drug) after SNI (a). In female animals, ANA-12 did 
not increase behavioral tactile thresholds, but vehicle treated SNI female mice were 
significantly less hypersensitive compared to ANA-12 treated animals, specifically on 
day 7 (4 and 6hrs after drug) post-SNI (b). Female ANA-12 and vehicle group had n=10 
each. Male ANA-12 group n=8, male vehicle group n=7.





























































Figure 2.6: Effects of ANA-12 (i.t.) on SNI induced pTrkB-ir in male and female 
mice 7 days post-SNI. Nerve injured male and female mice were tested pre-drug and 2 
hours post-drug (ANA-12(i.t.) or Veh) 7 days after injury (A). pTrkB-ir in spinal cords of 
these animals 4 hours after drug was quantified to determine the effects of the drug on 
TrkB activity (B). Unexpectedly, In males that show slight reduction in hypersensitivity 
at 2 hours after ANA-12(i.t) administration, ANA-12 increased pTrkB-ir in SNI operated 
males as compared to vehicle treated SNI males (p<0.05, Student’s t test). In contrast, 
female SNI mice in which the vehicle treatment showed mild anti-allodynic effect, 
pTrkB-ir in spinal cord was significantly higher in vehicle treated SNI females as 
compared to ANA-12 injected SNI females (p<0.05, Student’s t test). p<0.05* sample 
sizes: Male veh = 4 mice, male ANA-12 = 5 mice, female veh = 6, female ANA-12 = 5.
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Figure 2.7: Effects of intrathecal administration of ANA-12 and vehicle on spinal 
pTrkB-ir in naïve mice. Naïve, uninjured, male and female mice were injected with 
ANA-12 (i.t.), vehicle (i.t.), and saline (i.t.) and their tactile thresholds were measured, 
and no differences were detected due to drug treatment (a). pTrkB-ir in spinal cord was 
significantly higher in naïve ANA-12 injected females as compared to vehicle treated 
females (b). Significant sex differences were observed in terms of baseline pTrkB-ir and 
effects of ANA-12, with female mice expressing higher amount of pTrkB-ir at baseline 
(saline treated males vs females), or after ANA-12 treatment (b). Two-Way ANOVA 
with Tukey’s HSD, p<0.05*. N=6 per group, except Male saline group (n=5).
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Most studies that report TrkB activation after injury indirectly measure TrkB 
activity because reliable and validates antibodies directed against TrkB receptors and 
TrkB specific antagonists or blockers are rare. In this study, we measured the level of 
TrkB activity after nerve injury using a commercially available antibody directed against 
phosphorylated fl-TrkBY816. Validation efforts revealed that the antibody detects a 
phosphorylated protein with the same molecular weight as fl-TrkB receptor, whose 
immunoreactivity is reduced by TrkB antagonist treatment. These experiments allow for 
site, region, and injury specific evaluation of TrkB activity in spinal cord.  
TrkB function in nerve injury induced changes in male and female mice 
 The data presented here indicate that activation of TrkB in spinal cord following 
nerve injury is increased comparably in male and female mice, but the functional role of 
TrkB may differ between the sexes. A novel, small molecule, TrkB receptor specific 
antagonist, ANA-12, minimally but significantly reduced nerve injury-related 
hypersensitivity in male mice as compared to vehicle treated mice, however in females, 
the effects were reversed, and the vehicle treated group was significantly less 
hypersensitive at certain timepoints. This indicates that either the role of TrkB receptor or 
the function of the drug is different between males and females. 
Evaluating sex-specific effects of drug on TrkB activity 
  To understand and verify drug activity on spinal TrkB function, we collected 
spinal tissues from male and female injured mice injected with ANA-12 or vehicle 7 days 
post-SNI. ANA-12 had significant yet opposite effects in male and female mice. In 
males, ANA-12 increased pTrkB-ir in DH as compared to males that received vehicle. In 
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contrast, ANA-12 injected females had significantly reduced pTrkB-ir in DH as 
compared to vehicle treated females. These counterintuitive results raise several 
possibilities as to the role of BDNF-TrkB signaling after nerve injury.  
ANA-12 has opposite effect in male and female mice: ANA-12 was first 
characterized in male mice, and the only two reported uses of it in context of nerve injury 
tested it in males. Therefore, the pharmacological and pharmacodynamic properties of the 
drug have not been evaluated or tested in females.  
TrkB activation reduces behavioral hypersensitivity: Our results show that the 
modest reduction in hypersensitivity corresponded with increased pTrkB-ir in males, 
while the vehicle which produced mild hyperalgesic effect in females also increased 
pTrkB-ir, suggesting a positive relationship between antinociceptive effects and increased 
TrkB activation. These results seem to oppose the conventional framework which 
suggests that BDNF-TrkB signaling is responsible for pain behaviors, however, it is 
possible that the TrkB signaling has dual properties and that activation of a specific set of 
TrkB receptors act in opposition to the neuroplasticity promoting mechanisms.  
Misinterpretation of existing data: Just as validated antibodies for TrkB receptors 
are difficult to find, so are other tools to specifically manipulate TrkB function. Often, the 
role of TrkB or BDNF in specific area after nerve injury is evaluated using methods that 
indirectly influence BDNF or TrkB activity. For instance, the two reports of sex-
differences in neuroimmune signaling, and specifically BDNF-TrkB signaling in spinal 
cord were evaluated by eliminating microglia, inhibiting microglial function with non-
specific toxins, inhibiting activation of kinases present in multiple cell types using 
methods that do not spatially restrict their activity. Thus, the confluence of these effects 
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on the simple behavioral output does not provide information regarding the mechanism 
by which pain behavior is regulated in the context of injury. Furthermore, when these 
techniques are used, their effectiveness or specificity is not verified. Therefore, these 
methods are assumed to exert the intended effect on a system, but it is possible that the 
means used for experimental manipulations may have sex-, time-, region-, and context 
specific effects that go unnoticed, thus leading to a misinterpretation of the results.  
Dual role of BDNF-TrkB signaling in pain processing 
Although the data presented here seem to oppose established ideas of BDNF-
TrkB signaling, it is difficult to speculate or hypothesize how these sex-differences 
impact downstream signaling. Some reports find that BDNF signaling in certain contexts 
can reduce pain hypersensitivity, suggesting dual effects of the neurotrophic factor (Miki 
et al., 2000; Eaton et al., 2002). Furthermore, a study investigating the KCC2 channel 
reduction that is a downstream consequence of BDNF-TrkB signaling found that the 
changes were conserved in male and female mice, which indicated to them that although 
the BDNF-TrkB signaling may diverge at the level of microglial signaling, the 
downstream changes attributed to BDNF-TrkB are preserved in males and females 
(Mapplebeck et al., 2019). Therefore, although the pattern of TrkB activity and its role in 
tactile hypersensitivity might be different between male and female mice, the signaling 
pathways converge further down the signaling pathway. This also raises the possibility 
that sex-dependent, BDNF-TrkB independent mechanisms produce downstream changes 
like those initiated by BDNF-TrkB signaling and they have a common target. Studying 
the similarities and differences between signaling pathways in males and females can 
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tremendously accelerate identification of targets for novel therapeutics that are 
efficacious in males and females.  
Sex-dependent injury-specific effects of ANA-12 and vehicle 
 Finally, we tested ANA-12 and the vehicle (2%DMSO and 33%PEG300 in 
Saline) in naïve mice and found that in females, vehicle suppressed TrkB activity and 
ANA-12 elevated back to levels comparable to saline controls. Similar patterns were 
present in males, but the effects did not reach significance. These data show that the 
nerve injury alters the BDNF-TrkB system, the drugs interact with that altered system in 
a sex-dependent manner. Additionally, there are certain baseline differences that should 
be considered since naïve females overall had higher TrkB activation in DH as compared 
to naïve males, a trend also seen in sham operated animals where females have higher 
TrkB activation compared to sham operated males.   
Taken together, the experiments in this chapter highlight the necessity for 
validation studies to understand sex-, time-, region-, assay-dependent patterns in 
signaling cascades. Furthermore, the results presented here can provide context, 
framework, and baseline data regarding the level of BDNF-TrkB activity in male and 
female animals, and the nuances of the signaling pathway in the two sexes.
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CHAPTER 3: ROLE OF SPINAL MICROGLIA IN INJURY INDUCED SPINAL 
BDNF-TRKB SIGNALING 
INTRODUCTION 
 Microglia and macrophages act as the first line of immune defense in the CNS 
and respond to damage or injury threat signals. Although peripheral monocytes and 
macrophages were thought to infiltrate the spinal cord following peripheral nerve injury, 
recent studies indicate that the increase in microglial markers in spinal cord is due to 
rapid proliferation and expansion of native microglia (Guan et al., 2015). Activated 
microglia serve many functions, including recruitment of other immune and glial cells, 
increased surveillance of CNS tissue, eliminating foreign object or damaged components 
(Milligan and Watkins, 2009). In the nerve injury literature, spinal microglia are 
considered important for their role in producing and releasing BDNF (Coull et al., 2005; 
Tsuda et al., 2005; Moalem and Tracey, 2006; Ji et al., 2013) which initiates a signaling 
cascade that ultimately results in disinhibition of spinal circuitry and increased 
nociceptive signaling (Ji et al., 2013).  
A few reports investigated the role and contribution of sensory neuron derived 
BDNF and found that it contributes minimally or partially to the injury induced 
hypersensitivity (Dembo et al., 2018; Sikandar et al., 2018). These studies highlight the 
importance of microglia as a source of BDNF, which is further supported by the fact that 
microglial inhibitors, or interventions aimed at blocking microglial function, significantly 
reduce pain behaviors in models of neuropathic pain (Jin et al., 2003; Raghavendra et al., 
2003; Tsuda et al., 2004; Ledeboer et al., 2005; Marchand et al., 2005; Zhuang et al., 
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2005; Clark et al., 2007; Zhang et al., 2011b; Zhou et al., 2011; Sorge et al., 2015). 
However, the exact role of microglia in signaling cascades following nerve injury has not 
been well-characterized.  
Despite the great interest in microglia for their role as BDNF producers and 
triggering long-term maladaptive neuroplasticity, there is no direct evidence to suggest 
microglia produce or release BDNF in vivo. Coull et al (2002) showed minimal BDNF 
release by ATP stimulated cultured microglia (Coull et al., 2005). Additional experiments 
included the intrathecal injection of ATP stimulated cultured microglia into rat spinal 
cords which produced behavioral hypersensitivity (Coull et al., 2005), however, these 
experiments did not test whether the pronociceptive effect of microglia were due to 
BDNF. Although, Ulmann (2008) performed immunohistochemistry to detect BDNF-ir, 
the antibody used was not validated by them or others, and additional tests were not 
presented to show specificity (Ulmann et al., 2008).  Other studies generally assume 
microglial BDNF release and design experiments under that assumption (Tsuda et al., 
2005; Moalem and Tracey, 2006; Ji et al., 2013). Sorge et al (2015) generated a 
tamoxifen inducible microglial BDNF knockout line to specifically study the role of 
microglial BDNF in pain behaviors but did not provide any evidence to show the degree 
of BDNF knockdown in these mice (Sorge et al., 2015). Finally, newer mouse lines 
designed to visualize BDNF expressing cells using genetically encoded fluorescent 
reporter proteins did not show reporter expression in microglia (Dembo et al., 2018). 
Therefore, expression of BDNF in spinal microglia has not been confirmed. Sex-
differences complicate the interpretation of these data since blocking, sequestering, or 
inhibiting BDNF activity seems to reverse hypersensitivity in male mice only, and 
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inducible genetic deletion of BDNF from microglia showed similar pattern of reduced 
hypersensitivity in males (Sorge et al., 2015). These data led to much speculation 
regarding the fundamental role of BDNF-TrkB signaling in female mice (Sorge and 
Totsch, 2016; Mapplebeck et al., 2017, 2018). However, since the exact role of microglia 
in BDNF-TrkB signaling in spinal cord is unknown, the mechanistic reason for the sex-
differences cannot be discovered.  
 Since some evidence indicates presence and release of BDNF from spinal 
microglia, it is possible that microglia do not themselves express BDNF but sequester 
extracellular BDNF via TrkB receptors. As discussed in an earlier chapter, TrkB 
receptors come in three forms. The fl-TrkB receptor contains an intracellular kinase 
domain which is thought to be responsible for intracellular signaling (Barbacid, 1994; 
Minichiello, 2009; Ohira and Hayashi, 2009). In contrast, the truncated forms were long 
thought to sequester BDNF thus acting as an antagonist to fl-TrkB by preventing its 
activation (Middlemas et al., 1991).  The truncated T1 receptor is known to internalize 
BDNF upon binding, the BDNF is then transported and rereleased in an activity-
dependent manner in DRG neuronal cultures.  
 We evaluated the expression of BDNF and TrkB mRNA in spinal microglia using 
a high sensitivity in situ hybridization assay. We did not detect any instances of BDNF 
mRNA signal overlapping with microglial profiles, however, TrkB mRNA in microglia 
was evident. Additional experiments to evaluate if microglial TrkB is activated after 
nerve injury. We found that much of the injury induced increase in pTrkB-ir was 
localized to spinal microglia in injured mice. This is a novel finding because microglia 
were thought to lack the fl-TrkB receptor. Finally, we tested the functional role of 
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microglial TrkB receptors in nerve injury-induced hypersensitivity using a mouse line 
which permits tamoxifen-inducible microglia-specific TrkB deletion. We confirmed the 
degree of KD since we did not see any behavioral differences due to microglial TrkB 
deletion. In all these experiments, we did not detect any sex-differences in terms of the 




All experiments were conducted in compliance with National Institutes of Health 
Guide for Care and Use of Laboratory Animals and approved by the University of 
Minnesota Institutional Animal Care and Use Committee. Animals were group house 4 
males per cage, and 5 females per cage in a temperate and humidity-controlled SPF 
facility on a 12-hour light/dark cycle. The animals had free access to food and water. 
Male and female 4–12-week-old mice of the following genotypes: ICR-WT (CD-1), 
C57/Bl6, Iba1-eGFP, Ai14, Cx3Cr1creERT2 XAi14, Cx3Cr1creERT2 X TrkBfl/fl. ICR (CD-
1) WT and C57/Bl6 mice were bred in house. Iba1-GFP, a transgenic line in which 
enhanced green fluorescent protein (EGFP) is controlled by the Iba1 promoter, generated 
on a C57/Bl6 background, were provided by Dr. Kohsaka, National Institute of 
Neuroscience, Tokyo, Japan (Hirasawa et al., 2005). Ai14, B6.Cg-Gt(ROSA)26Sortm9(CAG-
tdTomato)Hze/J (Stock Number #007909) mouse line was bred with B6.129P2(C)-
Cx3cr1tm2.1(cre/ERT2)Jung/J mouse (Stock Number #020940)from Jackson labs and the 
colony was maintained at the University of Minnesota vivarium. The TrkBfl/fl line was 
obtained from Dr. Lino Tessarollo, Center for Cancer Research, NCI, Frederick, MD 
21702109. Heterozygous Iba1-GFP, heterozygous Ai14, Cx3Cr1creERT2XAi14 mice 
heterozygous for both genes, Cx3Cr1creERT2XTrkBfl/fl heterozygous for Cre and 
homozygous TrkBfl/fl animals were used for the following experiments. 4-
hydroxytamoxifen (50mg/kg, i.p.) was injected for 3 consecutive days, starting 2 days 
before SNI and ending on the day of SNI surgeries. In experiments in which animals 
were treated with tamoxifen, all animals, including littermate controls were injected with 
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tamoxifen. A 10mg/ml solution of 4-OHT in corn oil was heated to 400C to dissolve the 
drug. 4-OHT solution was used within 5 days of dilution.  
Spared Nerve Injury (SNI) 
Tactile hypersensitivity was induced using the spared nerve injury (SNI) model as 
described by Decosterd and Woolf (Decosterd and Woolf, 2000). Mice were placed under 
isoflurane anesthesia in a recumbent position and the three terminal branches of the left 
sciatic nerve were exposed by bluntly dissecting the left thigh muscle. The common 
peroneal and tibial nerves were ligated using a 5.0 silk suture.  The peroneal and tibial 
nerves were cut 2 mm distal to the ligation site, leaving the sural nerve uninjured. Sham 
animals had the left sciatic nerve exposed without ligation or cutting of the nerves.  
Tactile Hypersensitivity 
Mice were brought into a quiet testing room and allowed to acclimate for about an 
hour before placing them on a wire mesh grid platform under a glass enclosure and 
allowed to acclimate for 30 mins prior to testing. Synthetic Von Frey filaments were used 
to apply force onto the lateral plantar surface of the left and right hind paw. Using the up-
down method as described by (Chaplan et al., 1994) and statistical framework by (Dixon, 
2012), the 50% withdrawal threshold was calculated wherein a positive withdrawal reflex 
was defined as a flinching, retracting, or withdrawing of the hind paw from the filament. 
Baseline tactile thresholds were measured for all animals in these experiments and 
measured again following nerve injury but prior to tissue collection.  
Spinal Cord and DRG tissue section preparation 
Mice were deeply anesthetized with isoflurane and perfused via the heart with 
calcium-free Tyrode’s solution (116mM NaCl, 5.4mM KCl, 1.6mM MgCl·26H2O, 
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0.4mM MgSO·47H2O, 1.4mM NaH2PO4, 5.6mM glucose, and 26mM Na2HCO3) 
followed by fixative (4% paraformaldehyde). Tissues were dissected, post-fixed 
overnight in (4% paraformaldehyde), then incubated in 10% sucrose. Spinal cords were 
embedded in OCT compound (Tissue-Tek), flash frozen using liquid CO2 and stored at -
80°C overnight. Sections were cut at 14 μm thickness using a cryostat microtome 
(OTF5000, Bright Instruments) and thaw mounted onto Superfrost Plus® microscope 
slides (Fischer Scientific). Sliced spinal cord were anatomically mapped to determine 
slides within the L3 and L4 spinal levels. Spinal cord and DRG slides were stored at -
20°C until further processing.  
RNAscope Processing and Probes 
Slides were prepared for RNAscope® processing using the RNAscope 
Fluorescent Multiplex v2 Kit (Cat. No.  323100). Briefly, slides were recovered from -
200 C, air-dried, and incubated in 4% paraformaldehyde for 5 mins. Tissue sections were 
dehydrated in ethanol solutions of increasing concentration (50%, 70%, 100% EthOH) 
for 5 mins in each solution. Slides were washed with 1X PBS for 2 mins then tissue 
sections were covered with hydrogen peroxide (ACDBio) for 10 mins. Slides were 
washed 4 times with distilled water, incubated in target retrieval reagent heated to ~960 C 
for 4 mins, washed again 4 times in distilled water, then submerges in fresh 100% ethanol 
for 5 mins. A hydrophobic barrier was drawn around the tissue and allowed to dry at 
room temperature for 30 mins. After drying, tissues were covered in RNAscope Protease 
III and placed in a warm 40°C humidified chamber for 15 mins. After removal from 
oven, slides were washed 4 times in distilled water.  
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Following slide and tissue preparation, mRNA was tagged using highly specific probes 
and associated fluorophores for visualization. Briefly, excess water was removed from 
slides and BDNF (cat# 424821) or NTRK2 (cat#423611), positive- and negative-control 
probes were added to separate slides and incubated for 2 hours at 40°C. Following 
incubation with probes, slides were washed 2 times in 1X wash buffer for 2 mins. Probe 
signal was amplified by incubating tissue sections with Multiplex FLv2 AMP1 and 
AMP2 for 30 mins, and in AMP3 for 15 mins at 40°C. Slides were washed 2 times in 1X 
wash buffer for 2 mins in between each amplification incubation and following the last 
amplification step. Horseradish peroxidase channel 1 (HRP-C1) signal was developed by 
covering tissue in RNAscope multiplex FL v2 HRP-C1 and incubated for 15 mins at 
40°C. Slides were washed for 2 mins with 1X wash buffer and Cyanine 3 (PerkinElmer) 
diluted in TSA buffer (1:1,500) was added to the slides. Slides were incubated with Cy3 
for 30 mins at 40°C. Slides were washed twice with 1X wash buffer for 2 mins, 
RNAscope multiplex v2 HRP blocker was added to the slides, incubated for 15 mins at 
40°C, then washed 2 times in 1X wash buffer for 2 mins. DAPI was added to the slides 
for 30 seconds and cover-slipped using FluoroSave reagent (EMD Biosciences, Inc.). 
Slides were stored at room temperature. RNAscope® 20zz probes were ordered from 
ACDbio. The Ms-BDNF probe targeting 729-1974 mRNA region which recognize a 
common portion of the BDNF protein in all of the different translated proteins  
(NM_007540.4) and Ms-NTRK2 probe targeting 668-1582 mRNA regions encoding for 




Tissue preparation for Immunohistochemistry 
Following behavioral assessment, mice were deeply anesthetized with isoflurane 
and perfused via the heart with calcium-free Tyrode’s solution (in mM: 116 NaCl, 5.4 
KCl, 1.6 MgCl2·6H20, 0.4 MgSO4·7H2O, 1.4 NaH2PO4, 5.6 glucose, and 26 
Na2HCO3) followed by fixative (4% paraformaldehyde and 0.2% picric acid in 0.1 M 
phosphate buffer, pH 6.9). The spinal cord was removed, cryoprotected in 10% sucrose 
overnight, covered with OCT and frozen using liquid CO2, and cryostat-sectioned into 14 
μm sections that were slide-mounted. Sections were preabsorbed in T/T/T buffer (TBS 
containing 0.2% Triton-X 100 and 0.2% Tween 20) for 30 min followed by incubation 
with a rabbit anti-pTrkB (Y816) 1:500 (Millipore Sigma-Aldrich ABN1381), along with 
Chicken anti-GFP (1:1000, Abcam ab13970) or Rat anti-tdTomato (1:1000) diluted in 
T/T/T overnight at 40C in a humidified chamber. Tissue sections were then washed 3X 10 
mins each in TBS and incubated with secondary antibody for 1 hour at room temperature 
in a humidified chamber. Slides that were incubated with Chicken anti-GFP and Rabbit 
anti-pTrkB antibodies, were incubated with Cy3 donkey anti-rabbit (1:300 Jackson labs) 
and Alexa488 donkey anti-chicken (1:100 Jackson labs), while the slides previously 
treated with rabbit anti-pTrkB and Rat anti-tdTomato antibodies were incubated in Cy3 
donkey anti-rat (1:300) and Alexa 488 donkey anti-rabbit (1:100) antibodies. Slides were 
then washed in TBS 3X10 mins each and cover slipped with FluorSaveTM (Millipore 





Image Acquisition and Analysis 
Images were captured using a confocal Nikon A1R multiphoton confocal 
microscope or Olympus Fluoview upright confocal microscope at the University of 
Minnesota Imaging Center, with guidance from Dr. Guillermo Marquis. All images were 
collected on the same day or consecutive days with identical settings for all groups for 
direct comparison. Three equally spaced spinal cord sections were imaged for each 
animal and values were averaged to obtain one value per animal for between group 
comparisons. All data were tested for normality and the appropriate test was chosen.  
Image Quantification 
All image quantification was conducted by an experimenter blinded to the 
treatment conditions or animal groupings using FIJI. Images were auto-thresholded using 
max entropy setting and ROI size, and the Area of measured signal (um2) as well as 
%Area of thresholded signal (measure of signal controlled for ROI size) were measured. 
Representative images were selected by finding the datapoint close to the mean to 
represent the average staining or fluorescence pattern. All representative images were 
manipulated to enhance brightness and contrast for visualization, however, all images 
across groups were adjusted similarly.  
Data Analysis 
Results from FIJI were stored as csv files and excel VBA macros were created to 
streamline the editing excel files to minimize human error. Prism 8 was used for all 
statistical analyses presented in this chapter and mean and SEM are graphed. 
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RESULTS 
BDNF and TrkB mRNA in microglia 
 To determine if we could detect BDNF mRNA in microglial profiles after nerve 
injury, we combined in situ hybridization to detect BDNF mRNA and 
immunohistochemistry to visualize spinal microglia in ipsilateral dorsal horn 3 days after 
nerve injury in male mice. We did not detect any overlap between BDNF mRNA (Figure 
3.1 a1) and Iba1-ir (figure 3.1 a2). Higher magnification images of ipsilateral DH of two 
other animals from this cohort 3 days after SNI are included as representative images 
from a set of images collected from about 10 nerve injured male and female mice (Fig. 
3.1 b, c). Therefore, overall, we did not detect any instances of BDNF mRNA overlap 
with spinal microglia in ICR WT males 3 days post-SNI.  
 In contrast to BDNF mRNA, we observed that TrkB mRNA colocalized with 
Iba1-ir profiles at day 3 post-SNI in ICR WT mice. A representative image from a female 
ICR WT mouse 3 days post-SNI shows TrkB mRNA (figure 3.2 a1) and Iba1-ir (figure 
3.2 a2) composite image (figure 3.2 a3). High-resolution magnified images were 
collected from several SNI and sham animals 3 days post-injury was collected to 
determine whether in the instances where TrkB mRNA appeared to overlap with Iba1-ir 
cell the TrkB mRNA was located inside the cell. One of these high-resolution magnified 
images are displayed in an orthogonal view (on the side panels) shows the intensity along 
the axis and confirmed that TrkB mRNA is located within the Iba1-ir positive nucleus 
(figure 3.2 b).   
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TrkB receptor expression and activity in microglia 
 Further confirmation of the expression of TrkB in microglia came from the 
observation of pTrkB-ir in microglia after SNI. Since the well validated and widely used 
antibody directed against Iba1 is grown in rabbit, we could not use the rabbit anti-pTrkB 
antibody that we validated (data presented in chapter 2). We attempted to visualize spinal 
microglia with other commercially available antibodies but recognized that 
immunohistochemistry would not allow visualization of microglial processes and often 
has a punctate or patchy staining pattern. Therefore, we utilized a transgenic mouse 
model in which GFP is driven by Iba1 promoter, and immunostained spinal cord sections 
from these mice at 3-, 7-, and 28-day post-SNI in male and female animals to determine 
the degree of pTrkB in microglia. Representative images of ipsilateral and contralateral 
dorsal horn at 7 days post-SNI show increased pTrkB-ir and Iba1-GFP staining in 
ipsilateral (figure 3.3 b1, b2) DH as compared to contralateral (figure 3.3 a1, a2), and a 
composite image shows the overlap (figure 3.3 a3 and b3). The total area of pTrkB-ir and 
Iba1-GFP in DH was measured as the percentage of the total area of DH ROI that is 
occupied by pTrkB-ir. DH contralateral to the nerve injury had little to no pTrkB signal 
which matched sham levels of pTrkB and was not quantified. Similarly, in the absence of 
nerve injury, contralateral DH in SNI animals or ipsilateral DH in sham operated animals 
had very little Iba1-GFP expression. The pTrkB-ir in DH of male and female mice was 
equally elevated at days 3-, 7-, and 28-days post SNI (figure 3.3 g). Concomitantly, the 
injured mice had increased area of Iba1-GFP profiles in the ipsilateral DH as compared to 
contralateral side and no sex differences at any time-points in the degree of microglial 
activation (as measured by the area of DH occupied by Iba1-GFP profiles) were detected 
(figure 3.3 d) or the pTrkB-ir in microglia (figure 3.3 e). Lastly, to determine whether the 
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data collected with this transgenic mouse line is generalizable to WT animals, we 
quantified pTrkB-ir in WT and Iba1-GFP mice and noticed that SNI induced increase in 
pTrkB-ir in ipsilateral DH of Iba1-GFP mice was much greater than that seen in WT SNI 
mice (p<0.0001, One way ANOVA with Sidak’s post hoc, figure 3.3 f). Data from male 
and female mice were combined for comparisons between genotypes because no sex-
differences were detected in any of the groups. 
 Since we noticed significant effect of genotype on pTrkB-ir with the Iba1-GFP 
mouse line, we used another transgenic line to visualize microglial profiles and 
immunostain spinal cord tissue. This mouse line is a cross between a microglial 
tamoxifen inducible cre line (Cx3Cr1creERT2) and Ai14 (tdTomato reporter line). Naïve 
Cx3Cr1creERT2; Ai14 mice were injected with 50mg/kg (i.p.) tamoxifen for 3 consecutive 
days after baseline threshold measurement. On Day 3 of tamoxifen injections, SNI or 
sham surgeries were performed. Spinal cord tissue was collected 7 days post-SNI since 
previous studies measuring pTrkB-ir indicated peak levels at this timepoint. 
Representative images show pTrkB-ir in ipsilateral DH of SNI and sham operated 
animals (figure 3.4 a1, b1), along with staining for tdTomato protein to visualize 
microglial profiles (figure 3.4 a2, b2). A merged or composite image confirms the 
overlap between pTrkB-ir and endogenous fluorescence driven by a microglial promoter 
(figure 3.4 a3, b3). A slightly higher magnification image from a different SNI operated 
male mouse allows for better visualization of the fine microglial processes (figure 3.4 c2) 
and the pTrkB-ir (figure 3.4 c1) present in these regions (figure 3.4 c3). Image 
quantification revealed that SNI increased pTrkB-ir in females at day 7 post-SNI but not 
in males (p<0.05, Two-way ANOVA, Tukey’s HSD, figure 3.4 d). The overall area of 
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microglia in the DH was unchanged (figure 4.3 e), while the proportion of TrkB-ir in 
microglia was significantly higher in female SNI mice as compared to sham females 
(p<0.05, Two-Way ANOVA with Tukey’s HSD, figure 3.4 f). These data suggest that 
female system is more responsive to SNI induced immune changes, but the low sample 
size of the male groups cannot be ignored and likely skewed the results. Lastly, we 
compared SNI induced pTrkB-ir increase between C57/Bl6 WT and Cx3Cr1creERT2 X 
Ai14 mouse line on C57/Bl6 background which indicated that SNI increased pTrkB-ir to 
similar degrees in WT and transgenic mouse line used for better visualization of the 
entire microglial profile (figure 3.4 g). Unlike the Iba1-GFP line that expressed 
significantly higher pTrkBir, this transgenic mouse line does not differ from WT animals 
in its response to SNI induced TrkB activation. Furthermore, the proportion of overlap 
between pTrkB-ir and Iba1-GFP-ir was also higher in the Iba1-GFP line (Mean=56.3±6.8 
(SD) on day 7 post-SNI) as compared to the mean overlap value seen in Cx3Cr1creERT2 X 
Ai14 mouse line (Mean = 37±6.6 (SD)).  
Functional role of microglial TrkB on SNI induced tactile hypersensitivity 
 Since we detected TrkB mRNA in microglia instead of BDNF mRNA and 
considerable portion of pTrkB-ir in microglial profiles after nerve injury, we next wanted 
to test whether the microglial TrkB is functionally required for maintaining nerve injury 
induced neuroplasticity. To determine functionality, a tamoxifen inducible microglial cre 
line was crossed with a homozygous TrkB floxed line to generate a mouse line in which 
microglia specific TrkB could be knocked down in a time-dependent manner without 
affecting normal neural development. Cx3Cr1CreERT2/+; TrkBfl/fl mice or Cx3Cr1+/+;TrkBfl/fl 
(littermate controls) were tested to establish baseline tactile thresholds and injected with 
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50mg/kg (i.p) of 4-OHT (hydroxytamoxifen) once daily for 3 consecutive days. On third 
day of 4-OHT treatment, SNI surgeries were performed, and tactile thresholds were 
measured on days 3-, 7-, and 28- post-SNI. Behavioral testing did not show any sex- or 
treatment- differences between any of the groups on the side ipsilateral (figure 3.5 a) or 
contralateral to the injury (figure 3.5 b).  
To verify the degree of microglial TrkB mRNA knockdown, spinal cord tissues 
were collected on day 29 post-SNI and RNAscope was performed for quantification. 
Representative images of ipsilateral DH from Cx3Cr1creERT2/+; TrkBfl/fl (henceforth 
referred to cre+ or microglial TrkB KO, figure 3.6 b1-4) or Cx3Cr1+/+;TrkBfl/fl  
(henceforth referred to as cre- or littermake controls) SNI operated animals (figure 3.6 
a1-4). Surprisingly, overall BDNF and TrkB mRNA was unchanged in the cre+ animals 
(microglial TrkB KO) as compared to their cre- littermate controls that were treated with 
4-OHT and underwent SNI surgeries (figure 3.6 c, d). The microglial activation, defined 
by the area of DH occupied by Iba1-ir profiles, as well as proportion of TrkB mRNA in 
Iba1-ir profiles were significantly higher in male (p<0.01, Two-way ANOVA with 
Tukey’s HSD) and female (p<0.05, Two-way ANOVA with Tukey’s HSD) Cre+ animals 
as compared to their cre- counterparts (figure 3.6 e, f). These data indicate that microglia 
in DH of cre+ animals were more abundant and larger and occupied greater proportion of 
DH than microglia in cre- animals (figure 3.6 e). Similarly, the greater proportion of 
TrkB mRNA relative to DH ROI area, indicates higher proportion of TrkB mRNA in 
cre+ mice as compared to cre- mice (figure 3.6 f). The increased TrkB mRNA in cre+ 
DH might be due to a compensatory increase in TrkB mRNA in other cell types of the 
DH. To evaluate whether the TrkB mRNA density in microglia increases in cre+ animals, 
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the total area occupied by microglial portion of TrkB was normalized to the surface area 
of microglial profiles. When microglial TrkB mRNA was normalized to the size of 
microglia, the differences in animals of the two genotypes disappears (figures 3.6 g) 
which indicates that the increased TrkB mRNA was elevated proportionally with 
microglial profile expansion and proliferation.  
These data collectively indicate that our microglial TrkB KD strategy was either 
unsuccessful, or it produced a greater immune response that resulted in elevated TrkB 
mRNA expression that outweighed the KD, or both situations contributed to the 
increased TrkB mRNA in microglia. Although our experimental strategy was ineffective, 
the verification efforts elucidated the potential compensatory mechanisms that may be 




Figure 3.1: Visualization of BDNF mRNA in microglia. Representative images of 
DH sections collected from nerve injured ICR WT male mouse 3 days post-SNI (a1-
3). BDNF mRNA (a1), Iba1-ir (a2) and DAPI stain were used to determine whether 
BDNF mRNA colocalizes with microglial profiles (a3). Scale bar = 200um. Additional 
images were collected from SNI operated ICR WT animals 3 days post-SNI, two of the 
representative images are included (b, c) and these images do not contain any overlap of 
















Figure 3.2: Visualizing and verifying TrkB mRNA expression in spinal microglia.  
Representative images of DH of a male mouse 3 days post-SNI show TrkB mRNA 
visualized using RNAscope® (a1), Iba1-ir visualized using anti-Iba1 antibody (a2), and 
nuclei visualized with DAPI staining (a3) Scale bars = 200um. A high-resolution image 
of an Iba1-ir and DAPI positive profile was collected to confirm that TrkB mRNA was 
located inside DAPI stained Iba1-ir wrapped structure (b); An orthogonal view (side 
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Figure 3.3: Immunohistochemical analysis of pTrkB in spinal microglia using a 
Iba1-GFP transgenic mouse line. Representative image of pTrkB-ir and Iba1-GFP-ir in 
spinal DH contralateral (a1-3) and ipsilateral (b1-3) to nerve injury 7 days after SNI. 
pTrkB-ir (a1, b1) and Iba1-ir (a2, b2) in ipsilateral DH is higher as compared to the 
contralateral DH of the same animal. Scale bar = 200um, 20X magnification.  Composite 
image shows considerable overlap between pTrkB-ir and Iba1-ir in ipsilateral DH as 
compared to the contralateral DH (a3, b3). Quantification of the pTrkB-ir in ipsilateral 
DH of male and female animals at day 3-, day 7- and day 28-post SNI as a percent of 
total DH area shows similar levels of pTrkB-ir in male and female mice (g). The percent 
area of DH occupied by Iba1-ir was used as a measure of microglial activation (h), and 
the proportion of total pTrkB-ir overlap with Iba1-ir profiles was used to determine 
localization of pTrkB in microglia(i). No sex-differences were observed in any of these 
measures at any timepoint. pTrkB-ir in Iba1-GFP mice and balb/c WT littermate controls 
indicate a greater increase in pTrkB-ir in Iba1-GFP mice (j). One way ANOVA (WT 
sham vs WT SNI vs GFP SNI) with Tukey’s HSD. p<0.05*, p<0.0001****. Sample sizes 
(for g, h, i): 3day male (n=3), 3day female (n=5), day7 male (n=4), day7 female (n=6), 
28day male (n=3), 28day female (n=3).  Day 3: WT sham (n=4), WT SNI (n=5), GFP 
SNI (n=8). Day 7 GFP SNI (n=10). Day 28 WT SNI (n=6), GFP SNI (n=6).
 93 


































































































































Figure 3.4 Quantification of pTrkB-ir in spinal dorsal horn 7 days post-SNI in 
Cx3Cr1creERT2 X Ai14 mice and littermate controls. Representative images of 
ipsilateral DH from sham operated and SNI males 7 days post-SNI show higher pTrkB-ir 
(a1, b1) and microglial surface area visualized by microglial tdTomato expression (a2, 
b2) in injured animals. Higher magnification images collected from another animal at 7 
days post-SNI shows the presence of pTrkB-ir (c1) in microglial profiles (c2) in a 
composite image (c3) Scale bar = 200um. Quantification of pTrkB-ir in injured mice 
shows increased pTrkB in injured females compared to sham females at day 7 post-SNI 
(d). Similarly, the surface area of DH occupied by microglia and the proportion of 
microglial pTrkB was also higher in SNI females as compared to sham females (e, f). A 
comparison of SNI induced increase in pTrkB-ir in C57/Bl6 WT (male and female) vs the 
transgenic (male and female) mice created on the C57/Bl6 background did not show 
significant effect of genotype on pTrkB-ir (g). The data from male and female mice of 
each genotype were combined for following comparison between genotypes since sex-
differences were not observed within genotypes. Two-way ANOVA with Tukey’s post-
hoc test. p<0.05*, p<0.01**. Group sample sizes (d, e, f): Male sham (n=3), Male SNI 
(n=3), female sham (n=5), female SNI (n= 10). Sample size of WT sham (n=5), WT SNI 
(n=5), transgenic sham (n=8), transgenic SNI (n=13).
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Figure 3.5: Measurement of tactile thresholds in hind paws ipsilateral (a) and 
contralateral (b) to nerve injury in tamoxifen inducible microglial TrkB KO male 
and female mice along with littermate controls. Cx3Cr1creERT2/+ TrkBfl/fl (microglial 
TrkB KO) animals and littermate controls (Cx3Cr1+/+;TrkBfl/fl) were injected with 
50mg/kg (i.p) 4-OHT from day -2, -1, and 0 relative to SNI and tested days 3-, 7- and 28-
post-SNI did not show any reduction of behavioral hypersensitivity in microglial TrkB 
KO as compared to SNI operated control littermates (Two-way ANOVA). Number of 
animals: male Cre+ (n=17), male Cre- (n=13), female Cre+ (n=26), female Cre- (n=9).
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Figure 3.6: Evaluating degree of microglial TrkB knockdown in DH of spinal cord. 
Representative images of DH of Cx3Cr1+/+;TrkBfl/fl (control littermates a1-4) and 
Cx3Cr1CreERT2/+;TrkBfl/fl (microglial TrkB KO, b1-4) shows increased Iba1-ir and elevated 
TrkB mRNA in microglial TrkB KO mice. 25X magnification, scale bars = 200um. 
DAPI staining (a1,b1), Iba1-ir (a2, b2), TrkB mRNA (a3, b3), and merged image (a4, 
b4). The proportion of ipsilateral dorsal horn occupied by BDNF and TrkB mRNA in 
Cx3Cr1CreERT2/+;TrkBfl/fl tamoxifen treated SNI males and females as compared to SNI 
operated tamoxifen treated Cx3Cr1+/+;TrkBfl/fl (c,d) was not different between any of the 
groups. The area of DH occupied by iba1-ir profiles (e) and proportion of TrkB mRNA 
overlap with Iba1-ir cells (f) is higher in the Cre+ group as compared to their cre negative 
counterpart in males (p<0.01) and females (p<0.05) (Two-way ANOVA with Tukey’s 
HSD). However, when the area of microglial TrkB mRNA is normalized to the area of 
iba1+ profiles, there is no difference in the amount of microglial TrkB expression 
between groups (g). p<0.05*, p<0.01**. Sample sizes: Male Cre- (n= 5), male cre+ (n= 
8), female cre- (n= 4), female cre+ (n= 17).
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DISCUSSION 
 Microglia are considered an important cell type in nociceptive signaling due to 
their role in injury induced neuroplasticity. They are thought to contribute to the massive 
neural reorganization by releasing BDNF which on its own produces LTP, increases 
excitability of spinal neurons, and triggers a multitude of signaling cascades. However, 
there is no direct evidence indicating that microglia produce or express BDNF. One study 
measured miniscule amounts of BDNF release from neonatal cortical microglial cultures 
stimulated with ATP in vitro (Coull et al., 2005), and a follow up study performed 
immunohistochemical analysis on spinal cord dorsal horn to show BDNF-ir in microglia 
using an unvalidated anti-BDNF antibody (Ulmann et al., 2008). Most of the data that 
suggest the importance of microglia in BDNF-TrkB signaling include the study of 
functional changes in downstream effectors or behavior (Ulmann et al., 2008; Inoue, 
2009; Zhou et al., 2011; Chen et al., 2014b). In these instances, the contribution of 
microglia to the BDNF-TrkB signaling specifically is difficult to assess since microglia 
serve many other neuroprotective and pro-inflammatory roles in the CNS (Ledeboer et 
al., 2005; Moalem and Tracey, 2006; Vallejo et al., 2010; Ji et al., 2013; Ramesh et al., 
2013). Given the lack of clarity regarding the expression and release of BDNF, we aimed 
to use new and improved in situ hybridization method RNAscope® to visualize BDNF 
expression in microglia which would allow us to detect very small amounts of mRNA. 
We did not detect BDNF mRNA colocalization with microglial profiles, but instead we 
noted considerable microglial TrkB mRNA expression. The mRNA signal overlap with 
microglial profiles was not quantified because the tissue processing required for mRNA 
visualization destroys antigen epitopes, while tissue processing for IHC does not label 
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mRNA. Given this inverse relationship, to visualize both simultaneously, we 
underestimate both signals. This discrepancy is not problematic to demonstrate co-
localization, but any quantification of the overlap would not be informative or accurate. 
that was verified with high resolution imaging to confirm the localization of TrkB mRNA 
in nuclei of microglia. 
Limited information is available regarding the role of microglial BDNF-TrkB in 
injury induced maladaptive neuroplasticity. It is possible that microglia contribute to 
BDNF-TrkB signaling by engaging in an autocrine signaling loop that is triggered and 
maintained by continuous TrkB activation via fl-TrkB in microglia.  
 To determine the extent of injury induced changes in microglial TrkB activation, 
we utilized two transgenic mouse lines to genetically encode fluorescent molecules in 
microglia. Using these mouse lines, we discovered that about half of the activated TrkB 
signal can be localized to microglia. We confirmed the generalizability of these lines by 
comparing the injury induced changes in WT animals to estimate the degree of change in 
TrkB activation in genetically unaltered mice. Furthermore, we generated a tamoxifen 
inducible microglial TrkB knock-out line to selectively delete microglial TrkB around the 
time of injury and test its requirement on the development and maintenance of behavioral 
hypersensitivity as well as spinal microglial activation. We found that microglial cre 
expressing mice had tactile thresholds that were indistinguishable from the control 
animals, suggesting that microglial TrkB is dispensable in spinal neuroplasticity that 
results in behavioral hypersensitivity. However, further characterization of the tissues 
from these mice confirmed that the experimental manipulations were either unsuccessful 
or had compensatory changes that increased microglial activation and pTrkB-ir in 
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animals that were supposed to lack microglial TrkB. One possible explanation is that a 
subset of spinal microglia and macrophages that do not express Cx3Cr1 transcription 
factor increase their own expression of TrkB which compensated for the lack of TrkB 
mRNA in cre+ mouse DHs. 
Taken together, these data present a complicated view of TrkB function in 
microglia but also the challenges of selectively manipulating receptor expression in 
specific cell types. Finally, the studies presented here also emphasize the need for data 
collection to verify success rate and efficacy of any manipulation or treatment employed 
in experimental manipulation. Collectively, the data presented here will significantly 
contribute to our collective understanding of the function of microglia in nociceptive 
circuitry and its involvement in BDNF-TrkB signaling. 
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OVERALL SUMMARY 
BDNF-TrkB signaling is widely studied for its role in neuroplasticity in general, 
and in maladaptive plasticity in nociceptive systems following nerve injury. The wide 
range of studies investigating functional consequences of exogenous BDNF application 
or sequestration of endogenous BDNF on the system of interest (Miki et al., 2000; Eaton 
et al., 2002; Coull et al., 2005; Constandil et al., 2011; Chen et al., 2014b; Ding et al., 
2015; Li et al., 2017; Wu et al., 2021), provide evidence for the myriad of short- and 
long-term changes in neural signaling that can be attributed to BDNF. Despite the 
ubiquity of research on effects of BDNF, very little direct evidence of its expression 
(Geng et al., 2010), localization, and regulation after nerve injury exists. Similarly, the 
evidence for the BDNF receptor, TrkB, is also lacking. Given the importance of this 
signaling system in producing a chronic neuropathic pain state, we aimed to understand 
the expression patterns of the two molecules, as well as any injury induced changes in its 
expression and functional roles of this signaling.   
Information presented in this thesis fills gaps in the existing literature regarding 
BDNF-TrkB signaling and provides a comprehensive characterization of expression 
patterns of these molecules and their activity. First, mRNA expression of BDNF and 
TrkB in DRG neurons, satellite cells, and spinal cord dorsal horn after nerve injury was 
examined in detail, along with TrkB protein expression in spinal cords of male and 
female mice (Chapter 1). The extent of TrkB activity following nerve injury in male and 
female animals was quantified and no sex-differences were detected in the degree of 
TrkB activation, which disputes the notion that female mice lack BDNF-TrkB signaling 
in spinal cord (Sorge et al., 2015) (Chapter 2). The functional role of TrkB activity was 
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also investigated by using a TrkB inhibitor, ANA-12, and surprising results indicated an 
inverse relationship between TrkB activation and behavioral hypersensitivity in both 
sexes (Chapter 2). Lastly, high resolution images indicated an absence of BDNF mRNA 
in microglia, which contradicts the assumptions in the field regarding the source of 
BDNF (Tsuda et al., 2005; Moalem and Tracey, 2006; Ji and Suter, 2007; Scholz and 
Woolf, 2007; Vallejo et al., 2010; Sorge et al., 2015) in chronic neuropathic pain 
(Chapter 3). Interestingly, we detected TrkB mRNA in microglia, and conducted 
additional investigation to quantify the extent of TrkB activity in microglia after nerve 
injury and generated conditional knockout mice to determine the functional role of 
microglial TrkB in the injury-induced pain behaviors (Chapter 3). Collectively, these data 
provide a thorough characterization of the expression and activity patterns of BDNF and 
its receptor in a time- and sex-dependent manner in a model of chronic neuropathic pain.
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FUTURE DIRECTIONS 
BDNF and TrkB protein expression patterns  
Although we quantified TrkB protein levels (fl-TrkB and truncated TrkB) after 
nerve injury using Western blot assay, we could not detect TrkB levels via IHC due to the 
lack of validated antibodies. Future studies should utilize specific antibodies directed 
against the TrkB isoforms to understand its spatial expression patterns in the DH after 
injury. A similar study of the BDNF protein is crucial to our understanding of the role 
and mechanism by which BDNF participates in injury related changes. As mentioned 
previously, only few studies have attempted to measure BDNF levels in spinal cord, and 
even fewer have been able to successfully detect it. A careful and thorough 
characterization of BDNF protein expression and localization in different cell types of 
spinal cord is necessary for the fundamental understanding of the role of BDNF in 
neuroplasticity in a nociceptive system. A greater emphasis needs to be placed on 
development and testing of antibodies specific to BDNF and its receptors, and widely and 
uniformly used by different research groups to generate a cohesive narrative of the role of 
BDNF-TrkB signaling in chronic pain.  
TrkB function in injury induced hypersensitivity in male and female animals 
Disruption of BDNF activity rather than altering TrkB function is commonly used 
in studies of BDNF/TrkB signaling, mostly due to lack of proper TrkB tools. The only 
study in which TrkB activity was blocked included a transgenic line in which TrkB 
containing sensory neurons were photoablated (Dhandapani et al., 2018), while another 
generated a knock-in line in which the endogenous TrkB receptor was replaced with a 
genetically modified TrkB receptor that can be blocked with a synthetic ligand (Wang et 
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al., 2009).  Both studies included female mice, but either they did not detect and therefore 
did not report sex-differences, or any sex-differences were not highlighted or mentioned. 
This is an important point because other studies that manipulate microglial function 
(Sorge et al., 2015; Taves et al., 2016) have shown sex-differences, and this has led to the 
overinterpretation of the data considering the lack of information regarding BDNF-TrkB 
signaling in females. However, a recent study reported that changes downstream of 
BDNF-TrkB signaling, KCC2 channel downregulation, occurs in both sexes suggesting 
that pathways in male and female mice converge downstream of BDNF-TrkB 
(Mapplebeck et al., 2019). This could be due to an alternate pathway in females (separate 
from BDNF-TrkB) leads to the same downstream outcomes as BDNF-TrkB signaling 
accomplishes in males. Regardless of the pathways involved, the sites at which the male 
and female systems converge is crucial in developing therapeutic strategies for chronic 
pain that are effective in male and female systems.  
 New pharmacological tools to inhibit TrkB function need to be characterized and 
efficacy confirmed each time the drugs are used. Existing literature regarding 
contribution of TrkB signaling to neuronal excitability or downstream signaling pathways 
utilize a drug, K25a, assumed to be TrkB specific inhibitor, however it is now known to 
be a pan-Trk and PKC inhibitor. A novel small-molecule TrkB specific inhibitor (Cazorla 
et al., 2011) is now available but has not been widely used and therefore the stability, 
efficacy, and specificity of the drug has not been well characterized. In our experiments, 
ANA-12 had modest effects, but the vehicle required to dissolve the drug had unexpected 
side-effects that should be explored further. In addition, other studies that have reported 
using ANA-12 (Chen et al., 2014b; Moy et al., 2019) need to be transparent with their 
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methods sections and include control groups to determine existence of side-effects from 
the vehicle. Finally, additional experiments need to be done to determine the effect of the 
manipulations used to alter TrkB functions on the underlying neurophysiological systems 
to verify the treatment, tools, and reagents have similar effects in male and female 
animals.  
The role of Microglia in BDNF-TrkB signaling 
More research needs to be done to determine if spinal microglia produce BDNF 
and the exact role of microglia in BDNF-TrkB signaling. Although we did not detect 
BDNF mRNA using a highly sensitive and specific in situ hybridization method, we 
cannot rule out the possibility that BDNF mRNA is present in spinal microglia at levels 
that are below the detection limit of this method. Different assays may be required to 
visualize, quantify, and detect BDNF mRNA in microglia. Furthermore, additional 
studies are required to understand the role and function of microglial TrkB, and whether 
it is functionally relevant for nerve injury induced neuroplasticity. Given the variety of 
tools used to investigate function of BDNF-TrkB signaling, the efficacy and specificity of 
the manipulations should be verified.
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FINAL CONCLUSIONS 
Chronic pain affects millions of people in the US and costs billions in health care 
and lost productivity (CDC, 2018; CE et al., 2020). Neuropathic pain is notoriously 
difficult to treat, and current pain treatments are only about 60% effective (Stemkowski et 
al., 2013; Abdulrahman and Alsafi, 2020). Basic science research has provided and 
continues to generate new knowledge regarding the mechanisms underlying 
neuroplasticity in chronic pain (Khan and Smith, 2015; Abdulrahman and Alsafi, 2020). 
Many novel therapies have been developed based on the mechanistic information 
provided through pre-clinical research (Abdulrahman and Alsafi, 2020). BDNF continues 
to garner great interest as a potential target for pain therapies due to its involvement in 
many aspects and types of processes involved in maladaptive neuroplasticity underlying 
neuropathic pain. Data presented in this thesis contributes to the enormous literature on 
the role of BDNF-TrkB signaling in neuroplasticity that underlies chronic neuropathic 
pain. Specifically, this thesis provides a broad framework by evaluating BDNF and TrkB 
expression and function at multiple timepoints after nerve injury and in both sexes. 
Majority of the data in this field was collected only in male subjects, and often at a single 
timepoint or a single region of the CNS. Although the data presented here are by no 
means comprehensive, they do serve an important function in contextualizing existing 
literature on BDNF-TrkB activity, the role of microglia in this signaling, and a basic 
framework in which to interpret sex-differences in this signaling. A holistic and nuanced 
understanding of these neurobiological process is crucial for the development of therapies 
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